<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5297654</article-id><article-id pub-id-type="doi">10.3390/ijms18010019</article-id><article-id pub-id-type="publisher-id">ijms-18-00019</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Immunological Roles of Elevated Plasma Levels of Matricellular Proteins in Japanese Patients with Pulmonary Tuberculosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shiratori</surname><given-names>Beata</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00019">1</xref><xref ref-type="author-notes" rid="fn1-ijms-18-00019">&#x02020;</xref><xref ref-type="author-notes" rid="fn2-ijms-18-00019">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Jingge</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00019">1</xref><xref ref-type="author-notes" rid="fn1-ijms-18-00019">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Okumura</surname><given-names>Masao</given-names></name><xref ref-type="aff" rid="af2-ijms-18-00019">2</xref></contrib><contrib contrib-type="author"><name><surname>Chagan-Yasutan</surname><given-names>Haorile</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00019">1</xref></contrib><contrib contrib-type="author"><name><surname>Yanai</surname><given-names>Hideki</given-names></name><xref ref-type="aff" rid="af3-ijms-18-00019">3</xref></contrib><contrib contrib-type="author"><name><surname>Mizuno</surname><given-names>Kazue</given-names></name><xref ref-type="aff" rid="af3-ijms-18-00019">3</xref></contrib><contrib contrib-type="author"><name><surname>Yoshiyama</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="af2-ijms-18-00019">2</xref></contrib><contrib contrib-type="author"><name><surname>Idei</surname><given-names>Tadashi</given-names></name><xref ref-type="aff" rid="af3-ijms-18-00019">3</xref></contrib><contrib contrib-type="author"><name><surname>Ashino</surname><given-names>Yugo</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00019">1</xref></contrib><contrib contrib-type="author"><name><surname>Nakajima</surname><given-names>Chie</given-names></name><xref ref-type="aff" rid="af4-ijms-18-00019">4</xref></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Yasuhiko</given-names></name><xref ref-type="aff" rid="af4-ijms-18-00019">4</xref></contrib><contrib contrib-type="author"><name><surname>Hattori</surname><given-names>Toshio</given-names></name><xref ref-type="aff" rid="af5-ijms-18-00019">5</xref><xref rid="c1-ijms-18-00019" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Blasi</surname><given-names>Francesco B.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-18-00019"><label>1</label>Division of Disaster-Related Infectious Diseases, International Research Institute of Disaster Science, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan; <email>beatabucekova@gmail.com</email> (B.S.); <email>zhaojingge1987@gmail.com</email> (J.Z.); <email>haorile@gmail.com</email> (H.C.-Y.); <email>ya82@yahoo.co.jp</email> (Y.A.)</aff><aff id="af2-ijms-18-00019"><label>2</label>Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, 3-1-24 Matsuyama, Kiyose, Tokyo 204-8533, Japan; <email>okumuram@fukujuji.org</email> (M.O.); <email>yoshiyamat@fukujuji.org</email> (T.Y.)</aff><aff id="af3-ijms-18-00019"><label>3</label>Department of Clinical Laboratory, Fukujuji Hospital, Japan Anti-Tuberculosis Association, 3-1-2 4 Matsuyama, Kiyose, Tokyo 204-8533, Japan; <email>yanaih@fukujuji.org</email> (H.Y.); <email>hiralin99@yahoo.co.jp</email> (K.M.); <email>ideit@fukujuji.org</email> (T.I.)</aff><aff id="af4-ijms-18-00019"><label>4</label>Division of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido University, North 20, West 10, Kita-ku, Sapporo, Hokkaido 001-0020, Japan; <email>cnakajim@czc.hokudai.ac.jp</email> (C.N.); <email>suzuki@czc.hokudai.ac.jp</email> (Y.S.)</aff><aff id="af5-ijms-18-00019"><label>5</label>Department of Health Science and Social Welfare, Kibi International University, 8 Igamachi, Takahashi 716-8508, Japan</aff><author-notes><corresp id="c1-ijms-18-00019"><label>*</label>Correspondence: <email>hattorit@kiui.ac.jp</email>; Tel./Fax: +81-086-622-9469</corresp><fn id="fn1-ijms-18-00019"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn><fn id="fn2-ijms-18-00019"><label>&#x02021;</label><p>Current address: KKR Tohoku Kosai Hospital, Kokubun-cho 2-3-11, Aoba-ku, Sendai-shi, Miyagi 980-0803, Japan.</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2017</year></pub-date><volume>18</volume><issue>1</issue><elocation-id>19</elocation-id><history><date date-type="received"><day>24</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2016</copyright-year><license><license-p><!--CREATIVE COMMONS-->This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Elevated matricellular proteins (MCPs), including osteopontin (OPN) and galectin-9 (Gal-9), were observed in the plasma of patients with Manila-type tuberculosis (TB) previously. Here, we quantified plasma OPN, Gal-9, and soluble CD44 (sCD44) by enzyme-linked immunosorbent assay (ELISA), and another 29 cytokines by Luminex assay in 36 patients with pulmonary TB, six subjects with latent tuberculosis (LTBI), and 19 healthy controls (HCs) from Japan for a better understanding of the roles of MCPs in TB. All TB subjects showed positive results of enzyme-linked immunospot assays (ELISPOTs). Spoligotyping showed that 20 out of 36 <italic>Mycobacterium tuberculosis</italic> (MTB) strains belong to the Beijing type. The levels of OPN, Gal-9, and sCD44 were higher in TB (positivity of 61.1%, 66.7%, and 63.9%, respectively) than in the HCs. Positive correlations between OPN and Gal-9, between OPN and sCD44, and negative correlation between OPN and ESAT-6-ELISPOT response, between chest X-ray severity score of cavitary TB and ESAT-6-ELISPOT response were observed. Instead of OPN, Gal-9, and sCD44, cytokines G-CSF, GM-CSF, IFN-&#x003b1;, IFN-&#x003b3;, IL-12p70, and IL-1RA levels were higher in Beijing MTB-infected patients. These findings suggest immunoregulatory, rather than inflammatory, effect of MCPs and can advance the understanding of the roles of MCPs in the context of TB pathology.</p></abstract><kwd-group><kwd>tuberculosis</kwd><kwd>osteopontin</kwd><kwd>galectin-9</kwd><kwd>CD44</kwd><kwd>Beijing genotype MTB</kwd></kwd-group></article-meta></front><body><sec id="sec1-ijms-18-00019"><title>1. Introduction</title><p>In 2000, Bornstein et al. proposed that there is a family of secreted extracellular matrix (ECM) proteins termed &#x0201c;matricellular&#x0201d; proteins to highlight their influence on cell-matrix interactions [<xref rid="B1-ijms-18-00019" ref-type="bibr">1</xref>]. Based on this definition, several proteins have now been identified as matricellular proteins (MCPs), including connective-tissue growth factors, galectins [<xref rid="B2-ijms-18-00019" ref-type="bibr">2</xref>] and osteopontin (OPN) [<xref rid="B3-ijms-18-00019" ref-type="bibr">3</xref>]. MCPs participate in wound repair, inflammation, and cancer progression by binding to their receptor [<xref rid="B3-ijms-18-00019" ref-type="bibr">3</xref>]. The multitasking aspects of MCPs are derived from the different structural proteins, cell-surface receptors, proteases, and cytokines with which these proteins come into contact in the local environment of various tissues.</p><p>Among infectious diseases, <italic>Mycobacterium tuberculosis</italic> (MTB) infection remains a global public threat due to its ability to evade the host immune system by various mechanisms, including inhibition of phagolysosome fusion within phagocytes or induction of anti-inflammatory cytokine secretion [<xref rid="B4-ijms-18-00019" ref-type="bibr">4</xref>]. Abnormal turnover of MCPs in the development of granulomas and cavities are the typical pulmonary manifestations of TB [<xref rid="B5-ijms-18-00019" ref-type="bibr">5</xref>], in which chronic inflammation is activated, leading to tissue damage and subsequent tissue remodeling [<xref rid="B6-ijms-18-00019" ref-type="bibr">6</xref>]. MCPs are expressed at low levels in normal adult tissues but are promptly up-regulated during tissue repair and remodeling processes [<xref rid="B7-ijms-18-00019" ref-type="bibr">7</xref>]. In a previous study, we observed the expression of OPN and Gal-9 in TB granuloma [<xref rid="B8-ijms-18-00019" ref-type="bibr">8</xref>]. We also confirmed the high level of plasma OPN in subjects with Manila genotype MTB from the Philippines [<xref rid="B9-ijms-18-00019" ref-type="bibr">9</xref>] and in TB patients from Indonesia [<xref rid="B8-ijms-18-00019" ref-type="bibr">8</xref>]. The intact form of OPN, also reported as full-length OPN (FL-OPN), is involved in the complex pathways of coagulation and fibrinolysis, where multiple sites of FL-OPN serve as a thrombin-cleaved target. During this process, the OPN fragments are produced. Among those fragments, proteolytic cleavage of FL-OPN by thrombin (between Arg168 and Ser169) generates a functional fragment of N-terminal thrombin-cleaved OPN (trOPN), which contains a cryptic binding site for integrins &#x003b1;9&#x003b2;1 and &#x003b1;4&#x003b2;1 that enhances the attachment of trOPN to integrins. Elevation of trOPN levels has been reported in the recovery phase of dengue virus infection [<xref rid="B10-ijms-18-00019" ref-type="bibr">10</xref>].</p><p>Galectin-9 (Gal-9), a &#x003b2;-galactoside-binding MCP that induces apoptosis, chemoattraction, and necrosis, stimulates bactericidal activity in mouse TB models by binding to its receptor, T-cell immunoglobulin and mucin domain-containing molecule-3 (Tim3) [<xref rid="B11-ijms-18-00019" ref-type="bibr">11</xref>,<xref rid="B12-ijms-18-00019" ref-type="bibr">12</xref>]. Tim3-expressing T cells accumulate during chronic TB infection, produce less IL-2 and TNF but more IL-10, and are functionally exhausted. Such T-cell exhaustion impairs immunity and is detrimental to the outcome of MTB infection [<xref rid="B13-ijms-18-00019" ref-type="bibr">13</xref>]. On the other hand, Gal-9 is reported to stimulate regulatory T cells and is produced by them in an autocrine manner, indicating that they have immunoregulatory functions [<xref rid="B14-ijms-18-00019" ref-type="bibr">14</xref>]. Gal-9 and Tim-3 expression in CD4<sup>+</sup> and CD8<sup>+</sup> T cells increases during TB infection in humans compared to healthy individuals [<xref rid="B15-ijms-18-00019" ref-type="bibr">15</xref>]. As a result, the recovery of T-cell function against MTB is associated with the blockage of TIM3 [<xref rid="B16-ijms-18-00019" ref-type="bibr">16</xref>]. The associations of Gal-9 with the severity of the diseases were also found in dengue virus [<xref rid="B17-ijms-18-00019" ref-type="bibr">17</xref>] and malaria infection [<xref rid="B18-ijms-18-00019" ref-type="bibr">18</xref>], suggesting that manipulation of Gal-9 signals has an immunotherapeutic potential and may represent an alternative approach to improving immune responses to infections and/or vaccines [<xref rid="B19-ijms-18-00019" ref-type="bibr">19</xref>]. Based on these findings, Gal-9 is proposed to be a soluble molecule responsible for an immune checkpoint [<xref rid="B20-ijms-18-00019" ref-type="bibr">20</xref>].</p><p>CD44, a polymorphic transmembrane glycoprotein encoded by a single gene located on chromosome 11, one of OPN receptors, is involved in signaling and in regulating immune responses, and contributes to clinical manifestations [<xref rid="B21-ijms-18-00019" ref-type="bibr">21</xref>]. Increased OPN and CD44 expression was reported in adult T-cell leukemia cells [<xref rid="B22-ijms-18-00019" ref-type="bibr">22</xref>]. Meanwhile, CD44 glycosylation directly controls binding affinity of Gal-9 for fibrin and for immobilized fibrinogen and, therefore, participates in a wide variety of cell-cell or cell-matrix interactions, including tumor invasion and metastases [<xref rid="B23-ijms-18-00019" ref-type="bibr">23</xref>]. CD44, along with CD25, is used to track early T-cell development in the thymus, and CD44 expression is an indicative marker for effector-memory T cells. Both functions involve a mechanism of CD44-regulated apoptosis resistance in T-cell subpopulations, namely T<sub>h</sub>1 cells [<xref rid="B24-ijms-18-00019" ref-type="bibr">24</xref>]. On the other hand, the sCD44 level in TB patients has not been examined.</p><p>Interferon &#x003b3; (IFN-&#x003b3;)-producing TB antigen-specific CD4<sup>+</sup> effector T cells and memory T cells can be monitored by an enzyme-linked immunospot assay (ELISPOT) [<xref rid="B25-ijms-18-00019" ref-type="bibr">25</xref>], in which galectin-9&#x02013;CD44 interaction enhances stability and function of adaptive regulatory T cells (Tregs), promoting Foxp3 expression and, therefore, suppressing effector T cell responses during infection [<xref rid="B26-ijms-18-00019" ref-type="bibr">26</xref>]. Spoligotyping methods have been applied to identify the Beijing genotype of MTB that has been demonstrated as an independent risk factor of treatment failure [<xref rid="B27-ijms-18-00019" ref-type="bibr">27</xref>]. In this study, results of various current diagnostic methods and clinical findings were also analyzed in view of the function of MCPs. Our results showed an important immunological role of elevated OPN, Gal-9, and sCD44 levels in MTB infection.</p></sec><sec id="sec2-ijms-18-00019"><title>2. Results</title><sec id="sec2dot1-ijms-18-00019"><title>2.1. Clinical Findings</title><p>The study includes 36 patients with active pulmonary TB, six LTBI patients, and 19 HCs. All HCs tested negative for T-SPOT.TB, and all TB patients tested positive for T-SPOT.TB. Laboratory data on the TB patients are summarized in <xref ref-type="table" rid="ijms-18-00019-t001">Table 1</xref>. The majority of TB patients had low values of hemoglobin and hematocrit. Analysis of differential blood cell counts in TB patients showed frequent neutrophilia and lymphocytopenia. Plasma C-reactive protein (CRP) levels were above the reference range in 32 (88.8%) TB patients. Among the 36 patients with active pulmonary TB, 20 and 16 were infected with Beijing and non-Beijing type MTB, respectively. Moreover, 16 non-Beijing MTB isolates were found to be Latin American-Mediterranean-9 strain (one patient) and T2 strain (one patient); EAI2_Manila strain (two patients) and T3-OSA strain (two patients); a new type of strain (five patients) and T1 strain (five patients).</p></sec><sec id="sec2dot2-ijms-18-00019"><title>2.2. Luminex and ELISA</title><p>Luminex assay was applied to determine the levels of pro-inflammatory markers that are important in cell signaling and promote systemic inflammation. The results showed high levels of IFN-&#x003b3;, IL-8, IP-10, and TNF-&#x003b1; in the TB group compared to HCs (<xref ref-type="table" rid="ijms-18-00019-t002">Table 2</xref>). Plasma levels of other 25 biomarkers were below the measurable levels or did not show differences among the groups. Plasma OPN, Gal-9, and sCD44 were significantly higher in TB patients than in HCs. Plasma Gal-9 and sCD44 concentrations were higher in patients with LTBI than in HCs. In contrast, despite low levels of OPN in both HCs and LTBI, there was no significant difference between patients with TB and patients with LTBI (<xref ref-type="fig" rid="ijms-18-00019-f001">Figure 1</xref>A&#x02013;C). Unlike OPN, the FL-OPN and trOPN levels in the TB group did not differ from those in the HCs (<xref ref-type="table" rid="ijms-18-00019-t002">Table 2</xref>). Spearman&#x02032;s correlation analysis revealed a significant correlation between OPN and Gal-9, and between sCD44 and OPN, but not between Gal-9 and sCD44 in TB patients (<xref ref-type="fig" rid="ijms-18-00019-f002">Figure 2</xref>D&#x02013;F). In TB patients, the levels of both OPN and sCD44 were associated with lymphocytopenia and the levels of CRP, IL-8, IP-10, and OPN significantly correlated with neutrophils, whereas sCD44 correlated with white blood cell counts and TNF-&#x003b1;, but such a correlation was not observed in HCs. In spite of the significant correlation between OPN and FL-OPN in the TB patients, OPN did not correlate with trOPN (<xref ref-type="fig" rid="ijms-18-00019-f003">Figure 3</xref>A,B). Although Gal-9 did not show a correlation with either OPN or sCD44 (<xref ref-type="table" rid="ijms-18-00019-t003">Table 3</xref>), there was a correlation of Gal-9 with alanine aminotransferase (ALT) and creatinine. Plasma OPN, Gal-9, and sCD44 did not discriminate between patients with Beijing and non-Beijing MTB (<xref ref-type="fig" rid="ijms-18-00019-f001">Figure 1</xref>G&#x02013;I).</p><p>Of the 29 cytokine/chemokine indicators examined in each group, 15 indicators (IL-1&#x003b1;, IL-1&#x003b2;, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12p40, IL-13, IL-15, IL-17A, MIP-1&#x003b1;, and TNF-&#x003b2;) were excluded from statistical analyses because their median levels were below the detection level. EGF, VEGF, MCP-1, MIP-1&#x003b2;, eotaxin, G-CSF, GM-CSF, IFN-&#x003b1;2, IL-12p70, and IL-1RA did not differ among the groups. OPN, Gal-9, and sCD44 differed between groups. FL-OPN and trOPN did not differ among the groups.</p></sec><sec id="sec2dot3-ijms-18-00019"><title>2.3. ELISPOTS</title><p>All HCs tested negative for ESAT-6 or CFP-10 because the SFC (cutoff = 6) was lower than the cutoff; none of them showed total SFC &#x02265; 8 in ESAT-6 and CFP-10 assays. In the TB group, one sample was negative for ESAT-6 (SFC = 5) and CFP-10 (SFC = 3); the total SFC was no less than 8, and the result was considered positive. In the LTBI group, one sample with negative Esat-6 (SFC = 5) and CFP-10 (SFC = 0) was considered indeterminate because total SFC was less than 8. Therefore, the sensitivity of ELISPOTs for TB and LTBI was 100% and 83.3%, respectively (<xref ref-type="fig" rid="ijms-18-00019-f001">Figure 1</xref>A). There was a negative correlation between ESAT-6 SFC and OPN levels (<xref ref-type="fig" rid="ijms-18-00019-f001">Figure 1</xref>B) in TB but not in LTBI (<xref ref-type="fig" rid="ijms-18-00019-f001">Figure 1</xref>C). Nonetheless, ESAT-6 did not correlate with either FL-OPN or trOPN (<xref ref-type="fig" rid="ijms-18-00019-f003">Figure 3</xref>C,D), nor was a correlation detected between OPN levels and CFP10. Moreover, none of 19 markers tested by Luminex showed any correlation with either ESAT-6 or CFP-10 responses.</p></sec><sec id="sec2dot4-ijms-18-00019"><title>2.4. Sensitivity and Specificity</title><p>ROC analysis revealed that OPN, Gal-9, sCD44, IP-10, and anti-TBGL IgG could discriminate active TB (ATB) from HC, in spite of varied discriminatory power indicated by an AUC comparison. IP-10 (92.6% sensitivity and 93.3% specificity) was more effective than OPN (<italic>p</italic> &#x0003c; 0.001) and anti-TBGL IgG (<italic>p</italic> &#x0003c; 0.05). sCD44 (63.9% sensitivity and 100% specificity) was more effective than OPN (<xref ref-type="table" rid="ijms-18-00019-t004">Table 4</xref>). Of note, in spite of greater discriminatory power of IP-10 and sCD44, there was no significant difference between these two tests (<xref ref-type="fig" rid="ijms-18-00019-f004">Figure 4</xref>B), nor was a difference found between OPN and anti-TBGL assays (<xref ref-type="fig" rid="ijms-18-00019-f004">Figure 4</xref>A). No valid discrimination was found between ATB and LTBI in terms of the MCPs due to small number of LTBI subjects (<xref ref-type="fig" rid="ijms-18-00019-f004">Figure 4</xref>C).</p></sec><sec id="sec2dot5-ijms-18-00019"><title>2.5. Clinical Biomarkers, Chest X-rays, and Genotype</title><p>OPN and sCD44 showed positive correlations with inflammatory markers and a negative correlation with lymphocyte counts (<italic>p</italic> &#x0003c; 0.001). On the contrary, Gal-9 levels did not show any correlation with inflammatory and hematological markers, but correlated positively with ALT and creatinine (<xref ref-type="table" rid="ijms-18-00019-t003">Table 3</xref>). Analysis of patients&#x02032; chest radiographs showed cavity formation in 12 (33.3%) patients. Patients with lung cavities had significantly lower levels of hemoglobin and hematocrit and a higher differential number of monocytes and higher CRP, anti-TBGL IgG, and IP-10 levels (<xref ref-type="table" rid="ijms-18-00019-t005">Table 5</xref>). In contrast, the levels of OPN, sCD44, and Gal-9 were not significantly higher in cavity-positive ATB subjects.</p><p>The CXR score correlated with a higher proportion or higher number of monocytes and IL-12p70. The CXR score in cavity-positive and cavity-negative TB patients was analyzed further. In the former subgroup, ESAT-6 SFC showed an inverse correlation with CXR (<xref ref-type="table" rid="ijms-18-00019-t006">Table 6</xref>). In the latter subgroup, IL-12p70 correlated with CXR (<xref ref-type="table" rid="ijms-18-00019-t006">Table 6</xref>). No significant differences in plasma OPN, Gal-9, or sCD44 were observed between subjects with Beijing and non-Beijing MTB (<xref ref-type="fig" rid="ijms-18-00019-f001">Figure 1</xref>G&#x02013;I). Nonetheless, higher G-CSF, GM-CSF, IFN-&#x003b1;, IFN-&#x003b3;, IL-12p70, and IL-1RA concentrations were detected in Beijing MTB subjects (<xref ref-type="table" rid="ijms-18-00019-t007">Table 7</xref>). Among these six makers, levels of IFN-&#x003b1;, IFN-&#x003b3;, and IL-1RA were higher in Beijing MTB subjects compared to the HCs (<xref ref-type="table" rid="ijms-18-00019-t007">Table 7</xref>, <italic>Kruskal-Wallis</italic> test, <italic>p</italic> &#x0003c; 0.05).</p></sec></sec><sec id="sec3-ijms-18-00019"><title>3. Discussion</title><p>It is known that cells producing IFN-&#x003b3; after stimulation with ESAT-6 and CFP-10 are CD4<sup>+</sup> effector memory cells in both HIV-infected [<xref rid="B28-ijms-18-00019" ref-type="bibr">28</xref>] and uninfected subjects [<xref rid="B29-ijms-18-00019" ref-type="bibr">29</xref>]. A very low proportion of MTB-specific effector T cells is found in the blood compared with the infected tissue, indicating the differences in the cellular immune response and regulatory mechanisms between focal sites and systemic levels [<xref rid="B30-ijms-18-00019" ref-type="bibr">30</xref>]. OPN is a multifunctional phosphorylated glycoprotein that is synthesized by a variety of immune and non-immune cells, and it participates in the balance between the T<sub>h</sub>1 and T<sub>h</sub>2 responses and in granulomatous reactions [<xref rid="B31-ijms-18-00019" ref-type="bibr">31</xref>,<xref rid="B32-ijms-18-00019" ref-type="bibr">32</xref>]. A negative correlation was observed between OPN and ESAT-6 ELISPOTs (<xref ref-type="fig" rid="ijms-18-00019-f001">Figure 1</xref>B), in addition to the negative correlation of OPN with lymphocyte counts (<xref ref-type="table" rid="ijms-18-00019-t003">Table 3</xref>), which could be explained by increased migration of lymphocytes toward the lesion in response to OPN signaling [<xref rid="B33-ijms-18-00019" ref-type="bibr">33</xref>]. OPN-induced T-cell migration may initiate suppression of hyperinflammation [<xref rid="B33-ijms-18-00019" ref-type="bibr">33</xref>] and prevent the contact between peripheral lymphocytes and MTB bacilli, to the extent of compartmentalization of MTB bacteria and lower risk of dissemination [<xref rid="B34-ijms-18-00019" ref-type="bibr">34</xref>,<xref rid="B35-ijms-18-00019" ref-type="bibr">35</xref>]. Since OPN showed a correlation with sCD44, one of the memory T-cell markers [<xref rid="B36-ijms-18-00019" ref-type="bibr">36</xref>], it may also reflect the activation of memory T cells in the lesion. Of note, we did not observe a correlation between OPN and a CFP-10 cellular response, in support of the discrepancies between results of ESAT-6 and CFP-10 assays [<xref rid="B37-ijms-18-00019" ref-type="bibr">37</xref>]. Nevertheless, the component of secreted OPN responsible for summoning T-cell immigration is still unknown. Therefore, we tested the correlation among ESAT-6 SFC, FL-OPN, and trOPN, which did not show a statistical association with one another. It is more than obvious that the FL-OPN level exceeds the trOPN level, in addition to a correlation between OPN and FL-OPN, suggesting that FL-OPN is responsible as one of components of OPN. Another culprit may be MMP-cleaved OPN [<xref rid="B32-ijms-18-00019" ref-type="bibr">32</xref>]. Nevertheless, these components were not demonstrated in this study.</p><p>OPN levels are higher in patients with extensive TB/HIV coinfection than in patients with a single disease of TB or HIV [<xref rid="B38-ijms-18-00019" ref-type="bibr">38</xref>]. HIV has been proposed to infect memory T cells preferentially, and efficient transfer of the R5 virus to effector memory T cells has also been observed [<xref rid="B39-ijms-18-00019" ref-type="bibr">39</xref>,<xref rid="B40-ijms-18-00019" ref-type="bibr">40</xref>]. We have reported the increased amount of OPN in an AIDS-TB case, though this patient showed lymphadenopathy and did not have granuloma of the lungs [<xref rid="B41-ijms-18-00019" ref-type="bibr">41</xref>]. Probably, OPN was synthesized in activated lymph nodes and immune cells in this patient, and we have reported that macrophages are the main producer in the lymph nodes of adult T-cell leukemia patients [<xref rid="B21-ijms-18-00019" ref-type="bibr">21</xref>]. In this particular case of AIDS/TB, OPN did not decrease after antiretroviral therapy despite the fall of the viral load [<xref rid="B41-ijms-18-00019" ref-type="bibr">41</xref>], and OPN was retained as a component of the immune reconstitution (IRIS) that takes place during antiretroviral therapy [<xref rid="B42-ijms-18-00019" ref-type="bibr">42</xref>]. These data suggest that OPN could be synthesized in response to both TB and HIV infection and serve as a marker of complex disease activity such as IRIS.</p><p>Gal-9 appeared to reflect disease severity as reported for other diseases, such as malaria and dengue, because of its association with ALT and creatinine [<xref rid="B17-ijms-18-00019" ref-type="bibr">17</xref>,<xref rid="B18-ijms-18-00019" ref-type="bibr">18</xref>] (<xref ref-type="table" rid="ijms-18-00019-t003">Table 3</xref>). The levels of ALT and creatinine are indicators of systemic severity of TB infection [<xref rid="B43-ijms-18-00019" ref-type="bibr">43</xref>]. The association of these molecules with Gal-9 in TB cases supports the idea that Gal-9 could either influence the outcome of MTB infection or indicate the state of disease [<xref rid="B44-ijms-18-00019" ref-type="bibr">44</xref>]. Like many immunological pathways, the Gal-9 pathway functions via binding of Gal-9 to its receptor TIM3 prior to the initiation of the MCP-mediated signaling, before regulation of intracellular antimicrobial processes and of long-term immunological memory, as well as physiological homeostasis [<xref rid="B45-ijms-18-00019" ref-type="bibr">45</xref>]. In vitro TIM3 blockade&#x02014;in co-culture experiments with MTB-infected macrophages from TB patients with or without HIV co-infection&#x02014;promotes bacterial killing and enhances IL-1&#x003b2; secretion by infected cells, as well as the IFN-&#x003b3; release by T cells [<xref rid="B12-ijms-18-00019" ref-type="bibr">12</xref>]. Therefore, the interaction of Gal-9 and TIM3 serves as an immune checkpoint rather than leading to inflammation [<xref rid="B20-ijms-18-00019" ref-type="bibr">20</xref>]. Regimens incorporating therapeutics targeting such immune checkpoints are urgently needed to improve the clinical management of multidrug-resistant TB (MDR-TB) when the TB drug options are diminished for patients with MDR-TB infection [<xref rid="B46-ijms-18-00019" ref-type="bibr">46</xref>]. Drugs enhancing T-cell activity, depleting Treg cells, and inhibiting the immune checkpoint have been reported, in agreement with the potential of targeting of the Gal-9&#x02013;TIM3 interaction.</p><p>In this study, for the first time, we reported a high plasma concentration of sCD44 in ATB compared to HCs, in the sense of discriminatory power comparable to that of IP-10 (<xref ref-type="fig" rid="ijms-18-00019-f004">Figure 4</xref>B, <italic>p</italic> &#x0003e; 0.05). The discriminatory power of sCD44 is higher than that of OPN. Nonetheless, like OPN and Gal-9, sCD44 is related to immune regulation. Without the recruitment of other non-MTB inflammatory diseases in this study, it is implausible to make a conclusion about the reliability of these markers for TB diagnosis. IP-10, a chemokine secreted from cells stimulated with interferon and lipopolysaccharides, is a chemoattractant for activated T cells [<xref rid="B47-ijms-18-00019" ref-type="bibr">47</xref>]. IP-10 concentrations correlated with the plasma OPN level (<xref ref-type="table" rid="ijms-18-00019-t003">Table 3</xref>). A similar finding has also been reported, except that decreased IP-10 and OPN levels were reported as markers of negative conversion in sputum smears. Nevertheless, only IP-10 correlates with CRP and inflammation [<xref rid="B48-ijms-18-00019" ref-type="bibr">48</xref>]. In our study, significantly higher levels of plasma IP-10 in cavitary TB patients (<xref ref-type="table" rid="ijms-18-00019-t005">Table 5</xref>), and the correlation between IP-10 and CXR score (<xref ref-type="table" rid="ijms-18-00019-t006">Table 6</xref>) are in agreement with IP-10&#x02019;s role as an inflammation inducer. In addition to an inflammatory marker of TB [<xref rid="B49-ijms-18-00019" ref-type="bibr">49</xref>], serum IP-10 also increased in chronic hepatitis C [<xref rid="B50-ijms-18-00019" ref-type="bibr">50</xref>] and autoimmune diseases [<xref rid="B51-ijms-18-00019" ref-type="bibr">51</xref>].</p><p>Beijing genotype MTB has been the most prevalent in East Asia [<xref rid="B52-ijms-18-00019" ref-type="bibr">52</xref>] because of its virulence and resistance to drugs and BCG vaccination. Treatment failure and relapse have also been found to be associated with Beijing genotype MTB [<xref rid="B53-ijms-18-00019" ref-type="bibr">53</xref>]. On the other hand, other researchers, and our group, have reported that the rates of MDR-MTB among Beijing and non-Beijing family strains are not statistically significantly different in Beijing MTB-predominant regions [<xref rid="B27-ijms-18-00019" ref-type="bibr">27</xref>,<xref rid="B54-ijms-18-00019" ref-type="bibr">54</xref>]. Highly intense inflammation of Beijing genotype MTB infection may be detected by assaying inflammatory cytokines. Nevertheless, we did not detect differences in IP-10, sCD44, OPN, or Gal-9 concentrations between Beijing and non-Beijing TB infections; plasma concentrations of other cytokines, including G-CSF, GM-CSF, IFN-&#x003b1;, IFN-&#x003b3;, IL-12p70, and IL-1RA, were found to be higher in Beijing MTB-infected subjects than in non-Beijing MTB-infected subjects. An increased level of IL-12p70 was found to be associated with a high CXR sore, in support of the more severe lung damage in Beijing MTB infection compared to non-Beijing MTB infection [<xref rid="B55-ijms-18-00019" ref-type="bibr">55</xref>]. G-CSF and GM-CSF also play a role in the regulation of macrophages and dendritic cells to facilitate granuloma in the development of a cavity [<xref rid="B56-ijms-18-00019" ref-type="bibr">56</xref>]. Therefore, a high percentage of patients with a cavity were observed in the Beijing MTB group (40%) compared to the non-Beijing MTB group (25%) in this study. Unlike those cytokines, MCPs are involved in not only inflammation, but also immune regulation, and their concentrations were not affected by the genotype of MTB in this study.</p></sec><sec id="sec4-ijms-18-00019"><title>4. Materials and Methods</title><sec id="sec4dot1-ijms-18-00019"><title>4.1. Study Subjects</title><p>The study was conducted at Double-Barred Hospital, Tokyo, Japan, and Tohoku University, Sendai, Japan, between May 2014 and 2015. The study protocol was approved by the Ethics Committee of Fukujuji Hospital, Japan Anti-Tuberculosis Association and Graduate School of Medicine (NO. 2014-1-122, January 2014), Tohoku University. Written informed consent was obtained from all the enrolled subjects. All of the procedures were conducted in accordance with the Declaration of Helsinki.</p><p>Patients with culture-confirmed TB diagnosis according to WHO guidelines [<xref rid="B57-ijms-18-00019" ref-type="bibr">57</xref>] were included in the active TB group (<italic>n</italic> = 36); none of these patients had taken anti-TB medication. Healthy control subjects (HCs; <italic>n</italic> = 19) had no TB-related symptoms, and exhibited negative T-SPOT.TB (Oxford Immunotec, Oxford, UK) results. Subjects who showed positive T-SPOT.TB results or were positive in Interferon-&#x003b3; release assays (IGRAs) and without TB clinical manifestations were categorized as patients with latent tuberculosis (LTBI; <italic>n</italic> = 6). Exclusion criteria were as follows: impossibility to obtain informed consent, cancer, and human immunodeficiency virus infection.</p><p>Each subject donated a 7-mL heparinized and 7-mL EDTA-treated peripheral-blood sample. The EDTA-blood samples were centrifuged within 30 min of collection, and plasma was stored at &#x02212;80 &#x000b0;C until further analyses. Heparinized blood samples were sent from Double-Barred Cross Hospital and delivered to Tohoku University by a courier service within 24 h. All laboratory data were obtained from patients&#x02019; medical records and at the point of sample collection.</p><p>The TB patients were categorized into cavity-positive or cavity-negative in accordance with the presence or absence of cavities on chest X-ray images. A scoring method was used on the basis of the affected lung area and the presence of a cavity in order to conduct the comparison of TB lung lesion severity. The score was calculated as the percentage of lung affected plus 40 if cavitation was present [<xref rid="B58-ijms-18-00019" ref-type="bibr">58</xref>].</p></sec><sec id="sec4dot2-ijms-18-00019"><title>4.2. Spoligotyping</title><p>To differentiate Beijing and non-Beijing genotypes of MTB, spoligotypes of clinical MTB isolates were determined as described previously [<xref rid="B19-ijms-18-00019" ref-type="bibr">19</xref>]. Acid-fast bacilli (AFB) smear staining and Ogawa medium culture were conducted to confirm the MTB infection. To identify the most prevalent genotype, DNA samples were isolated from the colonies in culture. One colony was picked and resuspended in 0.5 mL of Tris-EDTA. The mixture was subjected to a 95 &#x000b0;C boil-and-cool cycle for decontamination before processing for spoligotyping. Briefly, the DR region was amplified with a primer pair, and the polymerase chain reaction (PCR) products were hybridized to a set of 43 spacer-specific oligonucleotide probes, which were covalently bound to membranes. The spoligo-international type was determined by comparing spoligotypes with the international spoligotyping database [<xref rid="B20-ijms-18-00019" ref-type="bibr">20</xref>].</p></sec><sec id="sec4dot3-ijms-18-00019"><title>4.3. ELISPOTs</title><p>Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood samples over Ficoll-Paque Plus (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and resuspended in the AIM V medium (Gibco, Grand Island, NE, USA) at the concentration of 2.5 &#x000d7; 10<sup>5</sup> per 100 &#x000b5;L. <italic>M. tuberculosis</italic> infection was determined using T-SPOT.TB (Oxford Immunotec, Oxford, UK), according to the manufacturer&#x02019;s recommendation. A test result was considered reliable if the spot-forming cell (SFC) number in the positive-control well was &#x0003e;20, and in the negative control well was &#x0003c;10. Positive results were scored as positive if the SFC number of either ESAT-6 or CFP-10 well was &#x0003e;6. If the total number of SFCs of ESAT-6 and CFP-10 was &#x02264;8, the test result was considered indeterminate. Spots were counted with an automated Immunospot Analyzer, CTL (Cellular Technologies, Cleveland, OH, USA).</p></sec><sec id="sec4dot4-ijms-18-00019"><title>4.4. ELISA</title><p>Plasma concentrations of OPN were determined using the Human Osteopontin DuoSet ELISA Development System Kit (R and D Systems, Minneapolis, MN, USA) [<xref rid="B21-ijms-18-00019" ref-type="bibr">21</xref>]. In this ELISA kit, the proprietary capture monoclonal antibody and the detection polyclonal antibodies were both raised against recombinant human OPN (NS0-derived, amino acids Ile17-Asn300). To determine the full-length OPN and trOPN, two separate ELISA kits (IBL, Gunma, Japan) were used. In the FL-OPN kit, a polyclonal rabbit antibody (O-17) specific to the N terminus of OPN (Ile17-Gln31, accession # NP_000573.1) was used as a capture antibody, and a mouse monoclonal antibody (10A16) raised against synthetic peptides corresponding to the internal sequence of human OPN (Lys166-Glu187) served as a detector antibody. Therefore, this kit does not allow us to detect trOPN. Meanwhile, the trOPN ELISA assay was performed using an anti-trOPN monoclonal antibody (34E3) as the capture antibody, and the O-17 antibody as the detection antibody. This capture antibody specifically reacts to the epitope Ser162&#x02013;Arg168 exposed by thrombin and does not react with matrix metalloproteinase 3 or 7 (MMP-3 or -7)-cleaved N-terminal trOPN [<xref rid="B10-ijms-18-00019" ref-type="bibr">10</xref>,<xref rid="B59-ijms-18-00019" ref-type="bibr">59</xref>]. Gal-9 was quantified using a human Gal-9 ELISA kit (Galpharma Co., Ltd., Takamatsu, Japan), as described previously [<xref rid="B17-ijms-18-00019" ref-type="bibr">17</xref>]. The concentration of soluble CD44 was measured by means of the Human CD44 ELISA kit (Abcam, Cambridge, MA, USA), as described previously [<xref rid="B21-ijms-18-00019" ref-type="bibr">21</xref>]. Samples, reagents, and buffers were prepared according to the manufacturers&#x02032; manuals.</p></sec><sec id="sec4dot5-ijms-18-00019"><title>4.5. Luminex Assays</title><p>Twenty-nine cytokine and chemokine species, including epidermal growth factor (EGF), eotaxin, granulocyte macrophage-colony stimulating factor (GM-CSF), G-CSF, interferon-alpha2 (IFN-&#x003b1;), IFN-&#x003b3;, interleukin 1 alpha (IL-1&#x003b1;), IL-1&#x003b2;, IL-1 receptor antagonist (IL-1RA), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17a, IFN-&#x003b3;-inducible protein-10 (IP-10), monocyte chemotactic protein 1 (MCP-1), macrophage-inducible protein 1&#x003b1; (MIP-1&#x003b1;), MIP-1&#x003b2;, tumor necrosis factor &#x003b1; (TNF-&#x003b1;), TNF-&#x003b2;, and vascular endothelial growth factor (VEGF), in plasma were measured using a commercially available kit (Milliplex Human Cytokine and Chemokine multiplex assay kit, Merck Millipore, Billerica, MA, USA) by Luminex methods, as reported previously [<xref rid="B17-ijms-18-00019" ref-type="bibr">17</xref>]. The assay was performed according to manufacturer&#x02032;s instructions and the concentrations of cytokines/chemokines were calculated by comparing the assay readings with a five-parameter logistic standard curve on a Bioplex-200 instrument (Bio-Rad, Hercules, CA, USA). All of the results were expressed in pg/mL.</p></sec><sec id="sec4dot6-ijms-18-00019"><title>4.6. Data Analyses</title><p>Data are expressed as the median and range. Significance of differences for more than two groups was tested by the Kruskal&#x02013;Wallis analysis. Significance of differences between two groups was tested by the Mann-Whitney <italic>U</italic> analysis. Correlations were determined using Spearman&#x02032;s nonparametric test. These analyses were carried out in the GraphPad Prism 6 software (GraphPad, San Diego, CA, USA). Furthermore, receiver operating characteristic (ROC) curves were constructed to study the diagnostic utility of OPN, Gal-9, sCD44, and IP-10. The area under curve (AUC) and cutoff analyses were conducted by means of the MedCalc statistical software Version 16.8.4 (Ostend, Belgium). A difference was assumed to be significant at <italic>p</italic> &#x0003c; 0.05.</p></sec></sec><sec id="sec5-ijms-18-00019"><title>5. Conclusions</title><p>In conclusion, this study showed that the levels of OPN, Gal-9, sCD44, and IP-10 could help to understand the immune network of MCPs in TB, in addition to their diagnostic value in MTB infections, especially in the presence of a lung cavity. Higher plasma concentration of OPN in association with a low-ESAT-6-ELISPOT-response could help to understand the immunopathogenesis of TB. A high level of sCD44 and Gal-9 in MTB infection could also predict MTB-related inflammation and clinical severity.</p></sec></body><back><ack><title>Acknowledgments</title><p>We acknowledge Toshiro Niki from Department of Immunology, Kagawa University, Takamatsu, for his comments on the biological function of Gal-9, and Yuka Sasaki from Double-Barred Cross Hospital, for her assessment on clinical severity of TB patients. This research is supported by the Research Program on Emerging and Re-emerging Infectious Diseases from Japan Agency for Medical Research and development, AMED, Grant Number 16fk0108302h0003. In addition, this study was partially supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan for the Joint Research Program of the Research Center for Zoonosis Control at Hokkaido University and a special research grant from the International Research Institute of Disaster Science of Tohoku University.</p></ack><notes><title>Authors Contributions</title><p>Toshio Hattori conceived and designed the projects; Masao Okumura, Hideki Yanai, Kazue Mizuno, Takashi Yoshiyama, Tadashi Idei collected samples and performed clinical data analysis; Yugo Ashino and Jingge Zhao performed chest X-ray assessment; Haorile Chagan-Yasutan performed Luminex assays; Beata Shiratori performed ELISPOTs assay; Beata Shiratori and Jingge Zhao performed ELISA assays; Chie Nakajima and Yasuhiko Suzuki performed spoligotyping. All the authors analyzed the data, discussed the results and contributed to the proof-editing of the manuscripts; and Jingge Zhao wrote the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-18-00019"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bornstein</surname><given-names>P.</given-names></name><name><surname>Sage</surname><given-names>E.H.</given-names></name></person-group>
<article-title>Matricellular proteins: Extracellular modulators of cell function</article-title>
<source>Curr. Opin. Cell Biol.</source>
<year>2002</year>
<volume>14</volume>
<fpage>608</fpage>
<lpage>616</lpage>
<pub-id pub-id-type="doi">10.1016/S0955-0674(02)00361-7</pub-id>
<pub-id pub-id-type="pmid">12231357</pub-id></element-citation></ref><ref id="B2-ijms-18-00019"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elola</surname><given-names>M.T.</given-names></name><name><surname>Wolfenstein-Todel</surname><given-names>C.</given-names></name><name><surname>Troncoso</surname><given-names>M.F.</given-names></name><name><surname>Vasta</surname><given-names>G.R.</given-names></name><name><surname>Rabinovich</surname><given-names>G.A.</given-names></name></person-group>
<article-title>Galectins: Matricellular glycan-binding proteins linking cell adhesion, migration, and survival</article-title>
<source>Cell. Mol. Life Sci. CMLS</source>
<year>2007</year>
<volume>64</volume>
<fpage>1679</fpage>
<lpage>1700</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-007-7044-8</pub-id>
<?supplied-pmid 17497244?><pub-id pub-id-type="pmid">17497244</pub-id></element-citation></ref><ref id="B3-ijms-18-00019"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murphy-Ullrich</surname><given-names>J.E.</given-names></name><name><surname>Sage</surname><given-names>E.H.</given-names></name></person-group>
<article-title>Revisiting the matricellular concept</article-title>
<source>Matrix Biol. J. Int. Soc. Matrix Biol.</source>
<year>2014</year>
<volume>37</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1016/j.matbio.2014.07.005</pub-id>
<?supplied-pmid 25064829?><pub-id pub-id-type="pmid">25064829</pub-id></element-citation></ref><ref id="B4-ijms-18-00019"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deretic</surname><given-names>V.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Master</surname><given-names>S.</given-names></name><name><surname>Harris</surname><given-names>J.</given-names></name><name><surname>Roberts</surname><given-names>E.</given-names></name><name><surname>Kyei</surname><given-names>G.</given-names></name><name><surname>Davis</surname><given-names>A.</given-names></name><name><surname>de Haro</surname><given-names>S.</given-names></name><name><surname>Naylor</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>H.H.</given-names></name><etal/></person-group>
<article-title><italic>Mycobacterium tuberculosis</italic> inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism</article-title>
<source>Cell. Microbiol.</source>
<year>2006</year>
<volume>8</volume>
<fpage>719</fpage>
<lpage>727</lpage>
<pub-id pub-id-type="doi">10.1111/j.1462-5822.2006.00705.x</pub-id>
<?supplied-pmid 16611222?><pub-id pub-id-type="pmid">16611222</pub-id></element-citation></ref><ref id="B5-ijms-18-00019"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elkington</surname><given-names>P.T.</given-names></name><name><surname>Emerson</surname><given-names>J.E.</given-names></name><name><surname>Lopez-Pascua</surname><given-names>L.D.</given-names></name><name><surname>O'Kane</surname><given-names>C.M.</given-names></name><name><surname>Horncastle</surname><given-names>D.E.</given-names></name><name><surname>Boyle</surname><given-names>J.J.</given-names></name><name><surname>Friedland</surname><given-names>J.S.</given-names></name></person-group>
<article-title><italic>Mycobacterium tuberculosis</italic> up-regulates matrix metalloproteinase-1 secretion from human airway epithelial cells via a p38 MAPK switch</article-title>
<source>J. Immunol.</source>
<year>2005</year>
<volume>175</volume>
<fpage>5333</fpage>
<lpage>5340</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.175.8.5333</pub-id>
<?supplied-pmid 16210639?><pub-id pub-id-type="pmid">16210639</pub-id></element-citation></ref><ref id="B6-ijms-18-00019"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dheda</surname><given-names>K.</given-names></name><name><surname>Booth</surname><given-names>H.</given-names></name><name><surname>Huggett</surname><given-names>J.F.</given-names></name><name><surname>Johnson</surname><given-names>M.A.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Rook</surname><given-names>G.A.</given-names></name></person-group>
<article-title>Lung remodeling in pulmonary tuberculosis</article-title>
<source>J. Infect. Dis.</source>
<year>2005</year>
<volume>192</volume>
<fpage>1201</fpage>
<lpage>1209</lpage>
<pub-id pub-id-type="doi">10.1086/444545</pub-id>
<?supplied-pmid 16136463?><pub-id pub-id-type="pmid">16136463</pub-id></element-citation></ref><ref id="B7-ijms-18-00019"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cox</surname><given-names>T.R.</given-names></name><name><surname>Erler</surname><given-names>J.T.</given-names></name></person-group>
<article-title>Remodeling and homeostasis of the extracellular matrix: Implications for fibrotic diseases and cancer</article-title>
<source>Dis. Models Mech.</source>
<year>2011</year>
<volume>4</volume>
<fpage>165</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1242/dmm.004077</pub-id>
<?supplied-pmid 21324931?><pub-id pub-id-type="pmid">21324931</pub-id></element-citation></ref><ref id="B8-ijms-18-00019"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hasibuan</surname><given-names>F.M.</given-names></name><name><surname>Shiratori</surname><given-names>B.</given-names></name><name><surname>Senoputra</surname><given-names>M.A.</given-names></name><name><surname>Chagan-Yasutan</surname><given-names>H.</given-names></name><name><surname>Koesoemadinata</surname><given-names>R.C.</given-names></name><name><surname>Apriani</surname><given-names>L.</given-names></name><name><surname>Takahashi</surname><given-names>Y.</given-names></name><name><surname>Niki</surname><given-names>T.</given-names></name><name><surname>Alisjahbana</surname><given-names>B.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name></person-group>
<article-title>Evaluation of matricellular proteins in systemic and local immune response to <italic>Mycobacterium tuberculosis</italic> infection</article-title>
<source>Microbiol. Immunol.</source>
<year>2015</year>
<volume>59</volume>
<fpage>623</fpage>
<lpage>632</lpage>
<pub-id pub-id-type="doi">10.1111/1348-0421.12320</pub-id>
<?supplied-pmid 26337438?><pub-id pub-id-type="pmid">26337438</pub-id></element-citation></ref><ref id="B9-ijms-18-00019"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shiratori</surname><given-names>B.</given-names></name><name><surname>Leano</surname><given-names>S.</given-names></name><name><surname>Nakajima</surname><given-names>C.</given-names></name><name><surname>Chagan-Yasutan</surname><given-names>H.</given-names></name><name><surname>Niki</surname><given-names>T.</given-names></name><name><surname>Ashino</surname><given-names>Y.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Telan</surname><given-names>E.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name></person-group>
<article-title>Elevated OPN, IP-10, and neutrophilia in loop-mediated isothermal amplification confirmed tuberculosis patients</article-title>
<source>Mediat. Inflamm.</source>
<year>2014</year>
<volume>2014</volume>
<fpage>513263</fpage>
<pub-id pub-id-type="doi">10.1155/2014/513263</pub-id>
<?supplied-pmid 25378811?><pub-id pub-id-type="pmid">25378811</pub-id></element-citation></ref><ref id="B10-ijms-18-00019"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chagan-Yasutan</surname><given-names>H.</given-names></name><name><surname>Lacuesta</surname><given-names>T.L.</given-names></name><name><surname>Ndhlovu</surname><given-names>L.C.</given-names></name><name><surname>Oguma</surname><given-names>S.</given-names></name><name><surname>Leano</surname><given-names>P.S.A.</given-names></name><name><surname>Telan</surname><given-names>E.F.O.</given-names></name><name><surname>Kubo</surname><given-names>T.</given-names></name><name><surname>Morita</surname><given-names>K.</given-names></name><name><surname>Uede</surname><given-names>T.</given-names></name><name><surname>Dimaano</surname><given-names>E.M.</given-names></name><etal/></person-group>
<article-title>Elevated levels of full-length and thrombin-cleaved osteopontin during acute dengue virus infection are associated with coagulation abnormalities</article-title>
<source>Thromb. Res.</source>
<year>2014</year>
<volume>134</volume>
<fpage>449</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="doi">10.1016/j.thromres.2014.05.003</pub-id>
<?supplied-pmid 24861695?><pub-id pub-id-type="pmid">24861695</pub-id></element-citation></ref><ref id="B11-ijms-18-00019"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jayaraman</surname><given-names>P.</given-names></name><name><surname>Sada-Ovalle</surname><given-names>I.</given-names></name><name><surname>Beladi</surname><given-names>S.</given-names></name><name><surname>Anderson</surname><given-names>A.C.</given-names></name><name><surname>Dardalhon</surname><given-names>V.</given-names></name><name><surname>Hotta</surname><given-names>C.</given-names></name><name><surname>Kuchroo</surname><given-names>V.K.</given-names></name><name><surname>Behar</surname><given-names>S.M.</given-names></name></person-group>
<article-title>Tim3 binding to galectin-9 stimulates antimicrobial immunity</article-title>
<source>J. Exp. Med.</source>
<year>2010</year>
<volume>207</volume>
<fpage>2343</fpage>
<lpage>2354</lpage>
<pub-id pub-id-type="doi">10.1084/jem.20100687</pub-id>
<?supplied-pmid 20937702?><pub-id pub-id-type="pmid">20937702</pub-id></element-citation></ref><ref id="B12-ijms-18-00019"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sada-Ovalle</surname><given-names>I.</given-names></name><name><surname>Chavez-Galan</surname><given-names>L.</given-names></name><name><surname>Torre-Bouscoulet</surname><given-names>L.</given-names></name><name><surname>Nava-Gamino</surname><given-names>L.</given-names></name><name><surname>Barrera</surname><given-names>L.</given-names></name><name><surname>Jayaraman</surname><given-names>P.</given-names></name><name><surname>Torres-Rojas</surname><given-names>M.</given-names></name><name><surname>Salazar-Lezama</surname><given-names>M.A.</given-names></name><name><surname>Behar</surname><given-names>S.M.</given-names></name></person-group>
<article-title>The Tim3&#x02013;galectin 9 pathway induces antibacterial activity in human macrophages infected with <italic>Mycobacterium tuberculosis</italic></article-title>
<source>J. Immunol.</source>
<year>2012</year>
<volume>189</volume>
<fpage>5896</fpage>
<lpage>5902</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1200990</pub-id>
<?supplied-pmid 23180819?><pub-id pub-id-type="pmid">23180819</pub-id></element-citation></ref><ref id="B13-ijms-18-00019"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jayaraman</surname><given-names>P.</given-names></name><name><surname>Jacques</surname><given-names>M.K.</given-names></name><name><surname>Zhu</surname><given-names>C.</given-names></name><name><surname>Steblenko</surname><given-names>K.M.</given-names></name><name><surname>Stowell</surname><given-names>B.L.</given-names></name><name><surname>Madi</surname><given-names>A.</given-names></name><name><surname>Anderson</surname><given-names>A.C.</given-names></name><name><surname>Kuchroo</surname><given-names>V.K.</given-names></name><name><surname>Behar</surname><given-names>S.M.</given-names></name></person-group>
<article-title>Tim3 mediates T cell exhaustion during <italic>Mycobacterium tuberculosis</italic> infection</article-title>
<source>PLoS Pathog.</source>
<year>2016</year>
<volume>12</volume>
<elocation-id>e1005490</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1005490</pub-id>
<?supplied-pmid 26967901?><pub-id pub-id-type="pmid">26967901</pub-id></element-citation></ref><ref id="B14-ijms-18-00019"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oomizu</surname><given-names>S.</given-names></name><name><surname>Arikawa</surname><given-names>T.</given-names></name><name><surname>Niki</surname><given-names>T.</given-names></name><name><surname>Kadowaki</surname><given-names>T.</given-names></name><name><surname>Ueno</surname><given-names>M.</given-names></name><name><surname>Nishi</surname><given-names>N.</given-names></name><name><surname>Yamauchi</surname><given-names>A.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name><name><surname>Masaki</surname><given-names>T.</given-names></name><name><surname>Hirashima</surname><given-names>M.</given-names></name></person-group>
<article-title>Cell surface galectin-9 expressing th cells regulate Th17 and Foxp3+ treg development by galectin-9 secretion</article-title>
<source>PLoS ONE</source>
<year>2012</year>
<volume>7</volume>
<elocation-id>e48574</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0048574</pub-id>
<?supplied-pmid 23144904?><pub-id pub-id-type="pmid">23144904</pub-id></element-citation></ref><ref id="B15-ijms-18-00019"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Liao</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><etal/></person-group>
<article-title>Tim-3-expressing CD4<sup>+</sup> and CD8<sup>+</sup> T cells in human tuberculosis (TB) exhibit polarized effector memory phenotypes and stronger anti-TB effector functions</article-title>
<source>PLoS Pathog.</source>
<year>2012</year>
<volume>8</volume>
<elocation-id>e1002984</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1002984</pub-id>
<?supplied-pmid 23144609?><pub-id pub-id-type="pmid">23144609</pub-id></element-citation></ref><ref id="B16-ijms-18-00019"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sada-Ovalle</surname><given-names>I.</given-names></name><name><surname>Ocana-Guzman</surname><given-names>R.</given-names></name><name><surname>Perez-Patrigeon</surname><given-names>S.</given-names></name><name><surname>Chavez-Galan</surname><given-names>L.</given-names></name><name><surname>Sierra-Madero</surname><given-names>J.</given-names></name><name><surname>Torre-Bouscoulet</surname><given-names>L.</given-names></name><name><surname>Addo</surname><given-names>M.M.</given-names></name></person-group>
<article-title>Tim-3 blocking rescue macrophage and T cell function against <italic>Mycobacterium tuberculosis</italic> infection in HIV<sup>+</sup> patients</article-title>
<source>J. Int. AIDS Soc.</source>
<year>2015</year>
<volume>18</volume>
<fpage>20078</fpage>
<pub-id pub-id-type="doi">10.7448/IAS.18.1.20078</pub-id>
<?supplied-pmid 26486200?><pub-id pub-id-type="pmid">26486200</pub-id></element-citation></ref><ref id="B17-ijms-18-00019"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chagan-Yasutan</surname><given-names>H.</given-names></name><name><surname>Ndhlovu</surname><given-names>L.C.</given-names></name><name><surname>Lacuesta</surname><given-names>T.L.</given-names></name><name><surname>Kubo</surname><given-names>T.</given-names></name><name><surname>Leano</surname><given-names>P.S.</given-names></name><name><surname>Niki</surname><given-names>T.</given-names></name><name><surname>Oguma</surname><given-names>S.</given-names></name><name><surname>Morita</surname><given-names>K.</given-names></name><name><surname>Chew</surname><given-names>G.M.</given-names></name><name><surname>Barbour</surname><given-names>J.D.</given-names></name><etal/></person-group>
<article-title>Galectin-9 plasma levels reflect adverse hematological and immunological features in acute dengue virus infection</article-title>
<source>J. Clin. Virol.</source>
<year>2013</year>
<volume>58</volume>
<fpage>635</fpage>
<lpage>640</lpage>
<pub-id pub-id-type="doi">10.1016/j.jcv.2013.10.022</pub-id>
<?supplied-pmid 24239423?><pub-id pub-id-type="pmid">24239423</pub-id></element-citation></ref><ref id="B18-ijms-18-00019"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dembele</surname><given-names>B.P.</given-names></name><name><surname>Chagan-Yasutan</surname><given-names>H.</given-names></name><name><surname>Niki</surname><given-names>T.</given-names></name><name><surname>Ashino</surname><given-names>Y.</given-names></name><name><surname>Tangpukdee</surname><given-names>N.</given-names></name><name><surname>Shinichi</surname><given-names>E.</given-names></name><name><surname>Krudsood</surname><given-names>S.</given-names></name><name><surname>Kano</surname><given-names>S.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name></person-group>
<article-title>Plasma levels of galectin-9 reflect disease severity in malaria infection</article-title>
<source>Malar. J.</source>
<year>2016</year>
<volume>15</volume>
<fpage>403</fpage>
<pub-id pub-id-type="doi">10.1186/s12936-016-1471-7</pub-id>
<?supplied-pmid 27515948?><pub-id pub-id-type="pmid">27515948</pub-id></element-citation></ref><ref id="B19-ijms-18-00019"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Merani</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Elahi</surname><given-names>S.</given-names></name></person-group>
<article-title>The bitter side of sweet: The role of galectin-9 in immunopathogenesis of viral infections</article-title>
<source>Rev. Med. Virol.</source>
<year>2015</year>
<volume>25</volume>
<fpage>175</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.1002/rmv.1832</pub-id>
<?supplied-pmid 25760439?><pub-id pub-id-type="pmid">25760439</pub-id></element-citation></ref><ref id="B20-ijms-18-00019"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>A.C.</given-names></name><name><surname>Joller</surname><given-names>N.</given-names></name><name><surname>Kuchroo</surname><given-names>V.K.</given-names></name></person-group>
<article-title>Lag-3, Tim-3, and Tigit: Co-inhibitory receptors with specialized functions in immune regulation</article-title>
<source>Immunity</source>
<year>2016</year>
<volume>44</volume>
<fpage>989</fpage>
<lpage>1004</lpage>
<pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.001</pub-id>
<?supplied-pmid 27192565?><pub-id pub-id-type="pmid">27192565</pub-id></element-citation></ref><ref id="B21-ijms-18-00019"><label>21.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chagan-Yasutan</surname><given-names>H.</given-names></name><name><surname>Tsukasaki</surname><given-names>K.</given-names></name><name><surname>Takahashi</surname><given-names>Y.</given-names></name><name><surname>Oguma</surname><given-names>S.</given-names></name><name><surname>Harigae</surname><given-names>H.</given-names></name><name><surname>Ishii</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Fukumoto</surname><given-names>M.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name></person-group>
<article-title>Involvement of osteopontin and its signaling molecule CD44 in clinicopathological features of adult T cell leukemia</article-title>
<source>Leuk. Res.</source>
<year>2011</year>
<volume>35</volume>
<fpage>1484</fpage>
<lpage>1490</lpage>
<pub-id pub-id-type="doi">10.1016/j.leukres.2011.05.011</pub-id>
<?supplied-pmid 21645921?><pub-id pub-id-type="pmid">21645921</pub-id></element-citation></ref><ref id="B22-ijms-18-00019"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Yamada</surname><given-names>O.</given-names></name><name><surname>Kida</surname><given-names>S.</given-names></name><name><surname>Matsushita</surname><given-names>Y.</given-names></name><name><surname>Yamaoka</surname><given-names>S.</given-names></name><name><surname>Chagan-Yasutan</surname><given-names>H.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name></person-group>
<article-title>Identification of CD44 as a downstream target of noncanonical NF-kappab pathway activated by human T-cell leukemia virus type 1-encoded tax protein</article-title>
<source>Virology</source>
<year>2011</year>
<volume>413</volume>
<fpage>244</fpage>
<lpage>252</lpage>
<pub-id pub-id-type="doi">10.1016/j.virol.2011.02.021</pub-id>
<?supplied-pmid 21411116?><pub-id pub-id-type="pmid">21411116</pub-id></element-citation></ref><ref id="B23-ijms-18-00019"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alves</surname><given-names>C.S.</given-names></name><name><surname>Yakovlev</surname><given-names>S.</given-names></name><name><surname>Medved</surname><given-names>L.</given-names></name><name><surname>Konstantopoulos</surname><given-names>K.</given-names></name></person-group>
<article-title>Biomolecular characterization of CD44-fibrin(ogen) binding: Distinct molecular requirements mediate binding of standard and variant isoforms of CD44 to immobilized fibrin (ogen)</article-title>
<source>J. Biol. Chem.</source>
<year>2009</year>
<volume>284</volume>
<fpage>1177</fpage>
<lpage>1189</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M805144200</pub-id>
<?supplied-pmid 19004834?><pub-id pub-id-type="pmid">19004834</pub-id></element-citation></ref><ref id="B24-ijms-18-00019"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baaten</surname><given-names>B.J.</given-names></name><name><surname>Li</surname><given-names>C.R.</given-names></name><name><surname>Deiro</surname><given-names>M.F.</given-names></name><name><surname>Lin</surname><given-names>M.M.</given-names></name><name><surname>Linton</surname><given-names>P.J.</given-names></name><name><surname>Bradley</surname><given-names>L.M.</given-names></name></person-group>
<article-title>CD44 regulates survival and memory development in T<sub>h</sub>1 cells</article-title>
<source>Immunity</source>
<year>2010</year>
<volume>32</volume>
<fpage>104</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.1016/j.immuni.2009.10.011</pub-id>
<?supplied-pmid 20079666?><pub-id pub-id-type="pmid">20079666</pub-id></element-citation></ref><ref id="B25-ijms-18-00019"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goletti</surname><given-names>D.</given-names></name><name><surname>Butera</surname><given-names>O.</given-names></name><name><surname>Bizzoni</surname><given-names>F.</given-names></name><name><surname>Casetti</surname><given-names>R.</given-names></name><name><surname>Girardi</surname><given-names>E.</given-names></name><name><surname>Poccia</surname><given-names>F.</given-names></name></person-group>
<article-title>Region of difference 1 antigen-specific CD4<sup>+</sup> memory T cells correlate with a favorable outcome of tuberculosis</article-title>
<source>J. Infect. Dis.</source>
<year>2006</year>
<volume>194</volume>
<fpage>984</fpage>
<lpage>992</lpage>
<pub-id pub-id-type="doi">10.1086/507427</pub-id>
<?supplied-pmid 16960787?><pub-id pub-id-type="pmid">16960787</pub-id></element-citation></ref><ref id="B26-ijms-18-00019"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Thalhamer</surname><given-names>T.</given-names></name><name><surname>Franca</surname><given-names>R.F.</given-names></name><name><surname>Xiao</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Hotta</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>C.</given-names></name><name><surname>Hirashima</surname><given-names>M.</given-names></name><name><surname>Anderson</surname><given-names>A.C.</given-names></name><name><surname>Kuchroo</surname><given-names>V.K.</given-names></name></person-group>
<article-title>Galectin-9&#x02013;CD44 interaction enhances stability and function of adaptive regulatory T cells</article-title>
<source>Immunity</source>
<year>2014</year>
<volume>41</volume>
<fpage>270</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.011</pub-id>
<?supplied-pmid 25065622?><pub-id pub-id-type="pmid">25065622</pub-id></element-citation></ref><ref id="B27-ijms-18-00019"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>C.L.</given-names></name><name><surname>Ji</surname><given-names>B.Y.</given-names></name><name><surname>Zhang</surname><given-names>L.Z.</given-names></name><name><surname>Shao</surname><given-names>Y.Z.</given-names></name><name><surname>Jiang</surname><given-names>S.L.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Nakajima</surname><given-names>C.</given-names></name><name><surname>Fan</surname><given-names>C.L.</given-names></name><etal/></person-group>
<article-title>Genotypes and characteristics of clustering and drug susceptibility of <italic>Mycobacterium tuberculosis</italic> isolates collected in Heilongjiang province, China</article-title>
<source>J. Clin. Microbiol.</source>
<year>2011</year>
<volume>49</volume>
<fpage>1354</fpage>
<lpage>1362</lpage>
<pub-id pub-id-type="doi">10.1128/JCM.02274-10</pub-id>
<?supplied-pmid 21325562?><pub-id pub-id-type="pmid">21325562</pub-id></element-citation></ref><ref id="B28-ijms-18-00019"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chiacchio</surname><given-names>T.</given-names></name><name><surname>Petruccioli</surname><given-names>E.</given-names></name><name><surname>Vanini</surname><given-names>V.</given-names></name><name><surname>Cuzzi</surname><given-names>G.</given-names></name><name><surname>Pinnetti</surname><given-names>C.</given-names></name><name><surname>Sampaolesi</surname><given-names>A.</given-names></name><name><surname>Antinori</surname><given-names>A.</given-names></name><name><surname>Girardi</surname><given-names>E.</given-names></name><name><surname>Goletti</surname><given-names>D.</given-names></name></person-group>
<article-title>Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients</article-title>
<source>J. Infect.</source>
<year>2014</year>
<volume>69</volume>
<fpage>533</fpage>
<lpage>545</lpage>
<pub-id pub-id-type="doi">10.1016/j.jinf.2014.06.009</pub-id>
<?supplied-pmid 24975174?><pub-id pub-id-type="pmid">24975174</pub-id></element-citation></ref><ref id="B29-ijms-18-00019"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petruccioli</surname><given-names>E.</given-names></name><name><surname>Petrone</surname><given-names>L.</given-names></name><name><surname>Vanini</surname><given-names>V.</given-names></name><name><surname>Sampaolesi</surname><given-names>A.</given-names></name><name><surname>Gualano</surname><given-names>G.</given-names></name><name><surname>Girardi</surname><given-names>E.</given-names></name><name><surname>Palmieri</surname><given-names>F.</given-names></name><name><surname>Goletti</surname><given-names>D.</given-names></name></person-group>
<article-title>IFN&#x003b3;/TNF&#x003b1; specific-cells and effector memory phenotype associate with active tuberculosis</article-title>
<source>J. Infect.</source>
<year>2013</year>
<volume>66</volume>
<fpage>475</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="doi">10.1016/j.jinf.2013.02.004</pub-id>
<?supplied-pmid 23462597?><pub-id pub-id-type="pmid">23462597</pub-id></element-citation></ref><ref id="B30-ijms-18-00019"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brighenti</surname><given-names>S.</given-names></name><name><surname>Andersson</surname><given-names>J.</given-names></name></person-group>
<article-title>Local immune responses in human tuberculosis: Learning from the site of infection</article-title>
<source>J. Infect. Dis.</source>
<year>2012</year>
<volume>205</volume>
<fpage>S316</fpage>
<lpage>S324</lpage>
<pub-id pub-id-type="doi">10.1093/infdis/jis043</pub-id>
<?supplied-pmid 22448014?><pub-id pub-id-type="pmid">22448014</pub-id></element-citation></ref><ref id="B31-ijms-18-00019"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koguchi</surname><given-names>Y.</given-names></name><name><surname>Kawakami</surname><given-names>K.</given-names></name><name><surname>Uezu</surname><given-names>K.</given-names></name><name><surname>Fukushima</surname><given-names>K.</given-names></name><name><surname>Kon</surname><given-names>S.</given-names></name><name><surname>Maeda</surname><given-names>M.</given-names></name><name><surname>Nakamoto</surname><given-names>A.</given-names></name><name><surname>Owan</surname><given-names>I.</given-names></name><name><surname>Kuba</surname><given-names>M.</given-names></name><name><surname>Kudeken</surname><given-names>N.</given-names></name><etal/></person-group>
<article-title>High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis</article-title>
<source>Am. J. Respir. Crit. Care Med.</source>
<year>2003</year>
<volume>167</volume>
<fpage>1355</fpage>
<lpage>1359</lpage>
<pub-id pub-id-type="doi">10.1164/rccm.200209-1113OC</pub-id>
<?supplied-pmid 12574077?><pub-id pub-id-type="pmid">12574077</pub-id></element-citation></ref><ref id="B32-ijms-18-00019"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uede</surname><given-names>T.</given-names></name></person-group>
<article-title>Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases</article-title>
<source>Pathol. Int.</source>
<year>2011</year>
<volume>61</volume>
<fpage>265</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="doi">10.1111/j.1440-1827.2011.02649.x</pub-id>
<?supplied-pmid 21501293?><pub-id pub-id-type="pmid">21501293</pub-id></element-citation></ref><ref id="B33-ijms-18-00019"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Inoue</surname><given-names>M.</given-names></name><name><surname>Shinohara</surname><given-names>M.L.</given-names></name></person-group>
<article-title>Cutting edge: Role of osteopontin and integrin &#x003b1; V in T cell-mediated anti-inflammatory responses in endotoxemia</article-title>
<source>J. Immunol.</source>
<year>2015</year>
<volume>194</volume>
<fpage>5595</fpage>
<lpage>5598</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1500623</pub-id>
<?supplied-pmid 25972484?><pub-id pub-id-type="pmid">25972484</pub-id></element-citation></ref><ref id="B34-ijms-18-00019"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nau</surname><given-names>G.J.</given-names></name><name><surname>Chupp</surname><given-names>G.L.</given-names></name><name><surname>Emile</surname><given-names>J.F.</given-names></name><name><surname>Jouanguy</surname><given-names>E.</given-names></name><name><surname>Berman</surname><given-names>J.S.</given-names></name><name><surname>Casanova</surname><given-names>J.L.</given-names></name><name><surname>Young</surname><given-names>R.A.</given-names></name></person-group>
<article-title>Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection</article-title>
<source>Am. J. Pathol.</source>
<year>2000</year>
<volume>157</volume>
<fpage>37</fpage>
<lpage>42</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9440(10)64514-2</pub-id>
<pub-id pub-id-type="pmid">10880373</pub-id></element-citation></ref><ref id="B35-ijms-18-00019"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nau</surname><given-names>G.J.</given-names></name><name><surname>Guilfoile</surname><given-names>P.</given-names></name><name><surname>Chupp</surname><given-names>G.L.</given-names></name><name><surname>Berman</surname><given-names>J.S.</given-names></name><name><surname>Kim</surname><given-names>S.J.</given-names></name><name><surname>Kornfeld</surname><given-names>H.</given-names></name><name><surname>Young</surname><given-names>R.A.</given-names></name></person-group>
<article-title>A chemoattractant cytokine associated with granulomas in tuberculosis and silicosis</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1997</year>
<volume>94</volume>
<fpage>6414</fpage>
<lpage>6419</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.94.12.6414</pub-id>
<?supplied-pmid 9177232?><pub-id pub-id-type="pmid">9177232</pub-id></element-citation></ref><ref id="B36-ijms-18-00019"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>L.</given-names></name><name><surname>Gurnani</surname><given-names>K.</given-names></name><name><surname>Dicaire</surname><given-names>C.J.</given-names></name><name><surname>van Faassen</surname><given-names>H.</given-names></name><name><surname>Zafer</surname><given-names>A.</given-names></name><name><surname>Kirschning</surname><given-names>C.J.</given-names></name><name><surname>Sad</surname><given-names>S.</given-names></name><name><surname>Sprott</surname><given-names>G.D.</given-names></name></person-group>
<article-title>Rapid clonal expansion and prolonged maintenance of memory CD8<sup>+</sup> T cells of the effector (CD44<sup>high</sup> CD62l<sup>low</sup>) and central (CD44<sup>high</sup> CD62l<sup>high</sup>) phenotype by an archaeosome adjuvant independent of TLR2</article-title>
<source>J. Immunol.</source>
<year>2007</year>
<volume>178</volume>
<fpage>2396</fpage>
<lpage>2406</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.178.4.2396</pub-id>
<?supplied-pmid 17277146?><pub-id pub-id-type="pmid">17277146</pub-id></element-citation></ref><ref id="B37-ijms-18-00019"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gey van Pittius</surname><given-names>N.C.</given-names></name><name><surname>Warren</surname><given-names>R.M.</given-names></name><name><surname>van Helden</surname><given-names>P.D.</given-names></name></person-group>
<article-title>ESAT-6 and CFP-10: What is the diagnosis?</article-title>
<source>Infect. Immunity</source>
<year>2002</year>
<volume>70</volume>
<fpage>6509</fpage>
<lpage>6510</lpage>
<pub-id pub-id-type="doi">10.1128/IAI.70.11.6509-6511.2002</pub-id>
<pub-id pub-id-type="pmid">12379740</pub-id></element-citation></ref><ref id="B38-ijms-18-00019"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ridruechai</surname><given-names>C.</given-names></name><name><surname>Sakurada</surname><given-names>S.</given-names></name><name><surname>Yanai</surname><given-names>H.</given-names></name><name><surname>Yamada</surname><given-names>N.</given-names></name><name><surname>Kantipong</surname><given-names>P.</given-names></name><name><surname>Piyaworawong</surname><given-names>S.</given-names></name><name><surname>Dhepakson</surname><given-names>P.</given-names></name><name><surname>Khusmith</surname><given-names>S.</given-names></name><name><surname>Keicho</surname><given-names>N.</given-names></name></person-group>
<article-title>Association between circulating full-length osteopontin and IFN-&#x003b3; with disease status of tuberculosis and response to successful treatment</article-title>
<source>Southeast Asian J. Trop. Med. Public Health</source>
<year>2011</year>
<volume>42</volume>
<fpage>876</fpage>
<lpage>889</lpage>
<?supplied-pmid 22299470?><pub-id pub-id-type="pmid">22299470</pub-id></element-citation></ref><ref id="B39-ijms-18-00019"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schnittman</surname><given-names>S.M.</given-names></name><name><surname>Lane</surname><given-names>H.C.</given-names></name><name><surname>Greenhouse</surname><given-names>J.</given-names></name><name><surname>Justement</surname><given-names>J.S.</given-names></name><name><surname>Baseler</surname><given-names>M.</given-names></name><name><surname>Fauci</surname><given-names>A.S.</given-names></name></person-group>
<article-title>Preferential infection of CD4<sup>+</sup> memory T cells by human immunodeficiency virus type 1: Evidence for a role in the selective T-cell functional defects observed in infected individuals</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1990</year>
<volume>87</volume>
<fpage>6058</fpage>
<lpage>6062</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.87.16.6058</pub-id>
<?supplied-pmid 2385584?><pub-id pub-id-type="pmid">2385584</pub-id></element-citation></ref><ref id="B40-ijms-18-00019"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Groot</surname><given-names>F.</given-names></name><name><surname>van Capel</surname><given-names>T.M.</given-names></name><name><surname>Schuitemaker</surname><given-names>J.</given-names></name><name><surname>Berkhout</surname><given-names>B.</given-names></name><name><surname>de Jong</surname><given-names>E.C.</given-names></name></person-group>
<article-title>Differential susceptibility of naive, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission</article-title>
<source>Retrovirology</source>
<year>2006</year>
<volume>3</volume>
<fpage>52</fpage>
<pub-id pub-id-type="doi">10.1186/1742-4690-3-52</pub-id>
<?supplied-pmid 16916447?><pub-id pub-id-type="pmid">16916447</pub-id></element-citation></ref><ref id="B41-ijms-18-00019"><label>41.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chagan-Yasutan</surname><given-names>H.</given-names></name><name><surname>Saitoh</surname><given-names>H.</given-names></name><name><surname>Ashino</surname><given-names>Y.</given-names></name><name><surname>Arikawa</surname><given-names>T.</given-names></name><name><surname>Hirashima</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Usuzawa</surname><given-names>M.</given-names></name><name><surname>Oguma</surname><given-names>S.</given-names></name><name><surname>EF</surname><given-names>O.T.</given-names></name><name><surname>Obi</surname><given-names>C.L.</given-names></name><etal/></person-group>
<article-title>Persistent elevation of plasma osteopontin levels in hiv patients despite highly active antiretroviral therapy</article-title>
<source>Tohoku J. Exp. Med.</source>
<year>2009</year>
<volume>218</volume>
<fpage>285</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="doi">10.1620/tjem.218.285</pub-id>
<?supplied-pmid 19638732?><pub-id pub-id-type="pmid">19638732</pub-id></element-citation></ref><ref id="B42-ijms-18-00019"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Lifson</surname><given-names>J.D.</given-names></name><name><surname>Duan</surname><given-names>L.</given-names></name><name><surname>Schacker</surname><given-names>T.W.</given-names></name><name><surname>Reilly</surname><given-names>C.</given-names></name><name><surname>Carlis</surname><given-names>J.</given-names></name><name><surname>Estes</surname><given-names>J.D.</given-names></name><name><surname>Haase</surname><given-names>A.T.</given-names></name></person-group>
<article-title>Potential roles of follicular dendritic cell-associated osteopontin in lymphoid follicle pathology and repair and in B cell regulation in HIV-1 and SIV infection</article-title>
<source>J. Infect. Dis.</source>
<year>2005</year>
<volume>192</volume>
<fpage>1269</fpage>
<lpage>1276</lpage>
<pub-id pub-id-type="doi">10.1086/444430</pub-id>
<?supplied-pmid 16136472?><pub-id pub-id-type="pmid">16136472</pub-id></element-citation></ref><ref id="B43-ijms-18-00019"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eastwood</surname><given-names>J.B.</given-names></name><name><surname>Corbishley</surname><given-names>C.M.</given-names></name><name><surname>Grange</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Tuberculosis and the kidney</article-title>
<source>J. Am. Soc. Nephrol. JASN</source>
<year>2001</year>
<volume>12</volume>
<fpage>1307</fpage>
<lpage>1314</lpage>
<?supplied-pmid 11373356?><pub-id pub-id-type="pmid">11373356</pub-id></element-citation></ref><ref id="B44-ijms-18-00019"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berry</surname><given-names>M.P.</given-names></name><name><surname>Graham</surname><given-names>C.M.</given-names></name><name><surname>McNab</surname><given-names>F.W.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Bloch</surname><given-names>S.A.</given-names></name><name><surname>Oni</surname><given-names>T.</given-names></name><name><surname>Wilkinson</surname><given-names>K.A.</given-names></name><name><surname>Banchereau</surname><given-names>R.</given-names></name><name><surname>Skinner</surname><given-names>J.</given-names></name><name><surname>Wilkinson</surname><given-names>R.J.</given-names></name><etal/></person-group>
<article-title>An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis</article-title>
<source>Nature</source>
<year>2010</year>
<volume>466</volume>
<fpage>973</fpage>
<lpage>977</lpage>
<pub-id pub-id-type="doi">10.1038/nature09247</pub-id>
<?supplied-pmid 20725040?><pub-id pub-id-type="pmid">20725040</pub-id></element-citation></ref><ref id="B45-ijms-18-00019"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>S.H.</given-names></name><name><surname>Lange</surname><given-names>C.</given-names></name><name><surname>Rao</surname><given-names>M.</given-names></name><name><surname>Balaji</surname><given-names>K.N.</given-names></name><name><surname>Lotze</surname><given-names>M.</given-names></name><name><surname>Schito</surname><given-names>M.</given-names></name><name><surname>Zumla</surname><given-names>A.I.</given-names></name><name><surname>Maeurer</surname><given-names>M.</given-names></name></person-group>
<article-title>Progress in tuberculosis vaccine development and host-directed therapies&#x02014;A state of the art review</article-title>
<source>Lancet Respir. Med.</source>
<year>2014</year>
<volume>2</volume>
<fpage>301</fpage>
<lpage>320</lpage>
<pub-id pub-id-type="doi">10.1016/S2213-2600(14)70033-5</pub-id>
<pub-id pub-id-type="pmid">24717627</pub-id></element-citation></ref><ref id="B46-ijms-18-00019"><label>46.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Rao</surname><given-names>M.</given-names></name><name><surname>Dodoo</surname><given-names>E.</given-names></name><name><surname>Maeurer</surname><given-names>M.</given-names></name></person-group>
<article-title>Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis</article-title>
<source>BMC Med.</source>
<year>2016</year>
<volume>14</volume>
<elocation-id>89</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12916-016-0635-1</pub-id>
<?supplied-pmid 27301245?><pub-id pub-id-type="pmid">27301245</pub-id></element-citation></ref><ref id="B47-ijms-18-00019"><label>47.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dufour</surname><given-names>J.H.</given-names></name><name><surname>Dziejman</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>M.T.</given-names></name><name><surname>Leung</surname><given-names>J.H.</given-names></name><name><surname>Lane</surname><given-names>T.E.</given-names></name><name><surname>Luster</surname><given-names>A.D.</given-names></name></person-group>
<article-title>IFN-&#x003b3;-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking</article-title>
<source>J. Immunol.</source>
<year>2002</year>
<volume>168</volume>
<fpage>3195</fpage>
<lpage>3204</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.168.7.3195</pub-id>
<?supplied-pmid 11907072?><pub-id pub-id-type="pmid">11907072</pub-id></element-citation></ref><ref id="B48-ijms-18-00019"><label>48.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.A.</given-names></name><name><surname>Jia</surname><given-names>H.Y.</given-names></name><name><surname>Chen</surname><given-names>J.N.</given-names></name><name><surname>Cui</surname><given-names>G.Y.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Wei</surname><given-names>Y.F.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Uede</surname><given-names>T.</given-names></name><name><surname>Diao</surname><given-names>H.Y.</given-names></name></person-group>
<article-title>Decreased osteopontin expression as a reliable prognostic indicator of improvement in pulmonary tuberculosis: Impact of the level of interferon-&#x003b3;-inducible protein 10</article-title>
<source>Cell. Physiol. Biochem.</source>
<year>2015</year>
<volume>37</volume>
<fpage>1983</fpage>
<lpage>1996</lpage>
<pub-id pub-id-type="doi">10.1159/000438559</pub-id>
<?supplied-pmid 26584297?><pub-id pub-id-type="pmid">26584297</pub-id></element-citation></ref><ref id="B49-ijms-18-00019"><label>49.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petrone</surname><given-names>L.</given-names></name><name><surname>Cannas</surname><given-names>A.</given-names></name><name><surname>Vanini</surname><given-names>V.</given-names></name><name><surname>Cuzzi</surname><given-names>G.</given-names></name><name><surname>Aloi</surname><given-names>F.</given-names></name><name><surname>Nsubuga</surname><given-names>M.</given-names></name><name><surname>Sserunkuma</surname><given-names>J.</given-names></name><name><surname>Nazziwa</surname><given-names>R.A.</given-names></name><name><surname>Jugheli</surname><given-names>L.</given-names></name><name><surname>Lukindo</surname><given-names>T.</given-names></name><etal/></person-group>
<article-title>Blood and urine inducible protein 10 as potential markers of disease activity</article-title>
<source>Int. J. Tuberc. Lung Dis.</source>
<year>2016</year>
<volume>20</volume>
<fpage>1554</fpage>
<lpage>1561</lpage>
<pub-id pub-id-type="doi">10.5588/ijtld.16.0342</pub-id>
<?supplied-pmid 27776600?><pub-id pub-id-type="pmid">27776600</pub-id></element-citation></ref><ref id="B50-ijms-18-00019"><label>50.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petrone</surname><given-names>L.</given-names></name><name><surname>Chiacchio</surname><given-names>T.</given-names></name><name><surname>Vanini</surname><given-names>V.</given-names></name><name><surname>Petruccioli</surname><given-names>E.</given-names></name><name><surname>Cuzzi</surname><given-names>G.</given-names></name><name><surname>di Giacomo</surname><given-names>C.</given-names></name><name><surname>Pucci</surname><given-names>L.</given-names></name><name><surname>Montalbano</surname><given-names>M.</given-names></name><name><surname>Lionetti</surname><given-names>R.</given-names></name><name><surname>Testa</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>High urine IP-10 levels associate with chronic HCV infection</article-title>
<source>J. Infect.</source>
<year>2014</year>
<volume>68</volume>
<fpage>591</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="doi">10.1016/j.jinf.2014.02.008</pub-id>
<?supplied-pmid 24582930?><pub-id pub-id-type="pmid">24582930</pub-id></element-citation></ref><ref id="B51-ijms-18-00019"><label>51.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Antonelli</surname><given-names>A.</given-names></name><name><surname>Ferrari</surname><given-names>S.M.</given-names></name><name><surname>Corrado</surname><given-names>A.</given-names></name><name><surname>di Domenicantonio</surname><given-names>A.</given-names></name><name><surname>Fallahi</surname><given-names>P.</given-names></name></person-group>
<article-title>Autoimmune thyroid disorders</article-title>
<source>Autoimmun. Rev.</source>
<year>2015</year>
<volume>14</volume>
<fpage>174</fpage>
<lpage>180</lpage>
<pub-id pub-id-type="doi">10.1016/j.autrev.2014.10.016</pub-id>
<?supplied-pmid 25461470?><pub-id pub-id-type="pmid">25461470</pub-id></element-citation></ref><ref id="B52-ijms-18-00019"><label>52.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bifani</surname><given-names>P.J.</given-names></name><name><surname>Mathema</surname><given-names>B.</given-names></name><name><surname>Kurepina</surname><given-names>N.E.</given-names></name><name><surname>Kreiswirth</surname><given-names>B.N.</given-names></name></person-group>
<article-title>Global dissemination of the <italic>Mycobacterium tuberculosis</italic> W-Beijing family strains</article-title>
<source>Trends Microbiol.</source>
<year>2002</year>
<volume>10</volume>
<fpage>45</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1016/S0966-842X(01)02277-6</pub-id>
<pub-id pub-id-type="pmid">11755085</pub-id></element-citation></ref><ref id="B53-ijms-18-00019"><label>53.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parwati</surname><given-names>I.</given-names></name><name><surname>van Crevel</surname><given-names>R.</given-names></name><name><surname>van Soolingen</surname><given-names>D.</given-names></name></person-group>
<article-title>Possible underlying mechanisms for successful emergence of the <italic>Mycobacterium tuberculosis</italic> Beijing genotype strains</article-title>
<source>Lancet Infect. Dis.</source>
<year>2010</year>
<volume>10</volume>
<fpage>103</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1016/S1473-3099(09)70330-5</pub-id>
<pub-id pub-id-type="pmid">20113979</pub-id></element-citation></ref><ref id="B54-ijms-18-00019"><label>54.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Mi</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Liang</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Lv</surname><given-names>B.</given-names></name><name><surname>Yuan</surname><given-names>L.</given-names></name></person-group>
<article-title>Genotypes and drug susceptibility of <italic>Mycobacterium tuberculosis</italic> isolates in Shihezi, Xinjiang province, China</article-title>
<source>BMC Res. Notes</source>
<year>2012</year>
<volume>5</volume>
<elocation-id>309</elocation-id>
<pub-id pub-id-type="doi">10.1186/1756-0500-5-309</pub-id>
<?supplied-pmid 22713520?><pub-id pub-id-type="pmid">22713520</pub-id></element-citation></ref><ref id="B55-ijms-18-00019"><label>55.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kato-Maeda</surname><given-names>M.</given-names></name><name><surname>Shanley</surname><given-names>C.A.</given-names></name><name><surname>Ackart</surname><given-names>D.</given-names></name><name><surname>Jarlsberg</surname><given-names>L.G.</given-names></name><name><surname>Shang</surname><given-names>S.</given-names></name><name><surname>Obregon-Henao</surname><given-names>A.</given-names></name><name><surname>Harton</surname><given-names>M.</given-names></name><name><surname>Basaraba</surname><given-names>R.J.</given-names></name><name><surname>Henao-Tamayo</surname><given-names>M.</given-names></name><name><surname>Barrozo</surname><given-names>J.C.</given-names></name><etal/></person-group>
<article-title>Beijing sublineages of <italic>Mycobacterium tuberculosis</italic> differ in pathogenicity in the guinea pig</article-title>
<source>Clin. Vaccine Immunol.</source>
<year>2012</year>
<volume>19</volume>
<fpage>1227</fpage>
<lpage>1237</lpage>
<pub-id pub-id-type="doi">10.1128/CVI.00250-12</pub-id>
<?supplied-pmid 22718126?><pub-id pub-id-type="pmid">22718126</pub-id></element-citation></ref><ref id="B56-ijms-18-00019"><label>56.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Szeliga</surname><given-names>J.</given-names></name><name><surname>Daniel</surname><given-names>D.S.</given-names></name><name><surname>Yang</surname><given-names>C.H.</given-names></name><name><surname>Sever-Chroneos</surname><given-names>Z.</given-names></name><name><surname>Jagannath</surname><given-names>C.</given-names></name><name><surname>Chroneos</surname><given-names>Z.C.</given-names></name></person-group>
<article-title>Granulocyte-macrophage colony stimulating factor-mediated innate responses in tuberculosis</article-title>
<source>Tuberculosis</source>
<year>2008</year>
<volume>88</volume>
<fpage>7</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1016/j.tube.2007.08.009</pub-id>
<?supplied-pmid 17928269?><pub-id pub-id-type="pmid">17928269</pub-id></element-citation></ref><ref id="B57-ijms-18-00019"><label>57.</label><element-citation publication-type="webpage">
<article-title>Who Guidelines on Tuberculosis</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/publications/guidelines/tuberculosis/en/">http://www.who.int/publications/guidelines/tuberculosis/en/</ext-link></comment>
<date-in-citation>(accessed on 24 September 2016)</date-in-citation>
</element-citation></ref><ref id="B58-ijms-18-00019"><label>58.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ralph</surname><given-names>A.P.</given-names></name><name><surname>Ardian</surname><given-names>M.</given-names></name><name><surname>Wiguna</surname><given-names>A.</given-names></name><name><surname>Maguire</surname><given-names>G.P.</given-names></name><name><surname>Becker</surname><given-names>N.G.</given-names></name><name><surname>Drogumuller</surname><given-names>G.</given-names></name><name><surname>Wilks</surname><given-names>M.J.</given-names></name><name><surname>Waramori</surname><given-names>G.</given-names></name><name><surname>Tjitra</surname><given-names>E.</given-names></name><name><surname>Sandjaja</surname></name><etal/></person-group>
<article-title>A simple, valid, numerical score for grading chest X-ray severity in adult smear-positive pulmonary tuberculosis</article-title>
<source>Thorax</source>
<year>2010</year>
<volume>65</volume>
<fpage>863</fpage>
<lpage>869</lpage>
<pub-id pub-id-type="doi">10.1136/thx.2010.136242</pub-id>
<?supplied-pmid 20861290?><pub-id pub-id-type="pmid">20861290</pub-id></element-citation></ref><ref id="B59-ijms-18-00019"><label>59.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grassinger</surname><given-names>J.</given-names></name><name><surname>Haylock</surname><given-names>D.N.</given-names></name><name><surname>Storan</surname><given-names>M.J.</given-names></name><name><surname>Haines</surname><given-names>G.O.</given-names></name><name><surname>Williams</surname><given-names>B.</given-names></name><name><surname>Whitty</surname><given-names>G.A.</given-names></name><name><surname>Vinson</surname><given-names>A.R.</given-names></name><name><surname>Be</surname><given-names>C.L.</given-names></name><name><surname>Li</surname><given-names>S.H.</given-names></name><name><surname>Sorensen</surname><given-names>E.S.</given-names></name><etal/></person-group>
<article-title>Thrombin-cleaved osteopontin regulates hemopoietic stem and progenitor cell functions through interactions with &#x003b1;<sub>9</sub>&#x003b2;<sub>1</sub> and &#x003b1;<sub>4</sub>&#x003b2;<sub>1</sub> integrins</article-title>
<source>Blood</source>
<year>2009</year>
<volume>114</volume>
<fpage>49</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2009-01-197988</pub-id>
<?supplied-pmid 19417209?><pub-id pub-id-type="pmid">19417209</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-18-00019-f001" position="float"><label>Figure 1</label><caption><p>OPN, Gal-9 and sCD44 in groups under study. Comparison of plasma levels of OPN (<bold>A</bold>); Gal-9 (<bold>B</bold>); and sCD44 (<bold>C</bold>) among HC, LTBI, and TB patients. Correlations among OPN, Gal-9, and sCD44 in TB patients (<bold>D</bold>&#x02013;<bold>F</bold>); comparison of OPN (<bold>G</bold>); Gal-9 (<bold>H</bold>); and sCD44 (<bold>I</bold>) between Beijing and non-Beijing genotype.</p></caption><graphic xlink:href="ijms-18-00019-g001a"/><graphic xlink:href="ijms-18-00019-g001b"/></fig><fig id="ijms-18-00019-f002" position="float"><label>Figure 2</label><caption><p>ELISPOTs reaction and OPN levels. ELISPOT assays are plotted as the number of specific PBMCs against the indicated stimulus (<bold>A</bold>); a negative correlation was observed between the ELISPOT for ESAT-6 and OPN in TB (<bold>B</bold>); and this correlation was not seen in the LTBI group (<bold>C</bold>).</p></caption><graphic xlink:href="ijms-18-00019-g002"/></fig><fig id="ijms-18-00019-f003" position="float"><label>Figure 3</label><caption><p>OPN, full-length OPN, n-half OPN, and ESAT-6 SFC count in TB patients. A comparison of plasma levels of OPN with full-length OPN (<bold>A</bold>) and with n-half OPN (<bold>B</bold>); and a comparison of ESAT-6 ELISPOT SFC counts with full-length OPN (<bold>C</bold>) and with n-half OPN (<bold>D</bold>).</p></caption><graphic xlink:href="ijms-18-00019-g003"/></fig><fig id="ijms-18-00019-f004" position="float"><label>Figure 4</label><caption><p>Sensitivity and specificity analysis for OPN, anti-TBGL IgG, IP-10, and sCD44. Comparison between ATB and HCs (<bold>A</bold>,<bold>B</bold>), no significant difference between the areas under curve (AUC) of OPN and anti-TBGL IgG, IP-10, or sCD44, <italic>p</italic> &#x0003e; 0.05. Strong discriminatory power of IP-10 and sCD44; <italic>p</italic> &#x0003c; 0.0001 for both (<bold>A</bold>). Comparison between ATB and LTBI, no significant discriminatory power of OPN, Gal-9, and sCD44 in LTBI and ATB (<italic>p</italic> &#x0003e; 0.05) due to the inadequacy of LTBI subjects (<bold>C</bold>). No significant difference between the AUC of OPN and Gal-9, between Gal-9 and sCD44, but difference between OPN and sCD44 (<italic>p</italic> = 0.014) (<bold>C</bold>).</p></caption><graphic xlink:href="ijms-18-00019-g004"/></fig><table-wrap id="ijms-18-00019-t001" position="float"><object-id pub-id-type="pii">ijms-18-00019-t001_Table 1</object-id><label>Table 1</label><caption><p>Characteristics of HC, LTBI, and TB individuals.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HC (<italic>n</italic> = 19)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LTBI (<italic>n</italic> = 6)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TB (<italic>n</italic> = 36)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antropometric data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Age: year; median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (19&#x02013;67)</td><td align="center" valign="middle" rowspan="1" colspan="1">63 (36&#x02013;71)</td><td align="center" valign="middle" rowspan="1" colspan="1">59.5 (19&#x02013;86)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Gender: male; <italic>n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (63)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (83)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28 (78)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Laboratory findings: median (range)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;RBC (10<sup>6</sup>/&#x003bc;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">Male 4.5&#x02013;5.5;<break/> Female 4.0&#x02013;5.0</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">4.65 (4.35&#x02013;5.12)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.44 (2.72&#x02013;5.57)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.443</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Hemoglobin (g/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">14&#x02013;18</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">14.6 (14.2&#x02013;15.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">13.1 (8.9&#x02013;17.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.064</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Hematocrit (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">40&#x02013;48</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">43.6 (40.9&#x02013;46.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">39.65 (25.5&#x02013;51.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.059</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;WBC (10<sup>3</sup>/&#x003bc;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5&#x02013;11</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">7.64 (5.34&#x02013;9.96)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.33 (3.84&#x02013;16.22)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.945</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Neutrophil (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">38&#x02013;80</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">57.35(51.9&#x02013;75.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">75.2 (57.0&#x02013;89.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Lymphocyte (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">15&#x02013;40</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">33.1 (18.2&#x02013;39.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.1 (2.8&#x02013;34.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Monocyte (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4&#x02013;7</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (4.9&#x02013;7.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.9 (3.4&#x02013;11.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Eosinophil (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0&#x02013;8</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1 (0.4&#x02013;4.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.4 (0&#x02013;11.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.902</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Platelet (10<sup>3</sup>/&#x003bc;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">140&#x02013;390</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">267 (203&#x02013;280)</td><td align="center" valign="middle" rowspan="1" colspan="1">305 (125&#x02013;564)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.228</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;CRP (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">0&#x02013;0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">0.055 (0.04&#x02013;0.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (0.04&#x02013;21.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Genotype (Beijing strain MTB %)</td><td align="center" valign="middle" rowspan="1" colspan="1">73.0, year 2010, Japan</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">55.6</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;ALT (Units)</td><td align="center" valign="middle" rowspan="1" colspan="1">4&#x02013;37</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td><td align="center" valign="middle" rowspan="1" colspan="1">20.5 (11&#x02013;29)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (8&#x02013;103)</td><td align="center" valign="middle" rowspan="1" colspan="1">na</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Creatinine (mg/dL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5&#x02013;1.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.74 (0.42&#x02013;11)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71 (0.57&#x02013;0.86)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na</td></tr></tbody></table><table-wrap-foot><fn><p>Age differences among the groups were analyzed by the <italic>Kruskal-Wallis</italic> test, gender differences by the <italic>Chi-square</italic> test, and laboratory findings by the <italic>Mann-Whitney</italic> test; <italic>p</italic> &#x0003c; 0.05 means a significant difference; na: not applicable.</p></fn></table-wrap-foot></table-wrap><table-wrap id="ijms-18-00019-t002" position="float"><object-id pub-id-type="pii">ijms-18-00019-t002_Table 2</object-id><label>Table 2</label><caption><p>Biomarker levels measured by Luminex assay and ELISA in HCs and TB patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Biomarker</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HC</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TB</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">IFN&#x003b3; (pg/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.46 (0.42&#x02013;19.38)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.13 (2.12&#x02013;41)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0065</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IL-8 (pg/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.585 (0.38&#x02013;7.52)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.26 (0.6&#x02013;31.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IP-10 (pg/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">235.8 (132.2&#x02013;472.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">864.6 (219.3&#x02013;3051)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TNF&#x003b1; (pg/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.88 (2.83&#x02013;8.34)</td><td align="center" valign="middle" rowspan="1" colspan="1">10.11 (2.19&#x02013;24.83)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">OPN (ng/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">19.63 (9.31&#x02013;111.64)</td><td align="center" valign="middle" rowspan="1" colspan="1">28.62 (10.59&#x02013;170)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.012</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gal-9 (ng/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">14.0 (0&#x02013;120)</td><td align="center" valign="middle" rowspan="1" colspan="1">171.5 (0&#x02013;470)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">sCD44 (ng/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">118.57 (91.02&#x02013;141.41)</td><td align="center" valign="middle" rowspan="1" colspan="1">159.66 (98.89&#x02013;346.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">FL-OPN (nmol/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.20 (2.83&#x02013;14.45)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.75 (0.52&#x02013;43.91)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rtOPN (pmol/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0&#x02013;26.73)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.87 (0&#x02013;347.95)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;0.05</td></tr></tbody></table></table-wrap><table-wrap id="ijms-18-00019-t003" position="float"><object-id pub-id-type="pii">ijms-18-00019-t003_Table 3</object-id><label>Table 3</label><caption><p>Correlations of OPN, Gal-9, and sCD44 with other laboratory parameters and biomarkers in TB patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Measurements</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">OPN</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">sCD44</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gal-9</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">r (<italic>P</italic>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">r (<italic>P</italic>)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">r (<italic>P</italic>)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">WBC (10<sup>3</sup>/&#x003bc;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">0.388 (0.019)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neutrophil (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.517 (&#x0003c;0.0001)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lymphocyte (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.569 (&#x0003c;0.0001)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.558 (&#x0003c;0.0001)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CRP (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.757 (&#x0003c;0.0001)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.534 (0.001)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IL-8 (pg/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.474 (0.013)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.524 (0.005)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IP-10 (pg/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.420 (0.029)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.542 (0.003)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TNF&#x003b1;</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">0.446 (0.020)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ALT</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">0.375 (0.024)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cre</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.377 (0.023)</td></tr></tbody></table><table-wrap-foot><fn><p>Ns: not significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="ijms-18-00019-t004" position="float"><object-id pub-id-type="pii">ijms-18-00019-t004_Table 4</object-id><label>Table 4</label><caption><p>Sensitivity and specificity.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Analytes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Youden Index</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cutoff</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sensitivity (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Specificity (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">AUC</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Comparison</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">OPN</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4006</td><td align="center" valign="middle" rowspan="1" colspan="1">25.1</td><td align="center" valign="middle" rowspan="1" colspan="1">61.1</td><td align="center" valign="middle" rowspan="1" colspan="1">79</td><td align="center" valign="middle" rowspan="1" colspan="1">0.706</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>a</italic></bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>b</italic></bold></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gal-9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6667</td><td align="center" valign="middle" rowspan="1" colspan="1">120</td><td align="center" valign="middle" rowspan="1" colspan="1">66.7</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.798</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">sCD44</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6389</td><td align="center" valign="middle" rowspan="1" colspan="1">141.4</td><td align="center" valign="middle" rowspan="1" colspan="1">63.9</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">0.846</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>a</italic></bold></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IP-10</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8593</td><td align="center" valign="middle" rowspan="1" colspan="1">400.3</td><td align="center" valign="middle" rowspan="1" colspan="1">92.6</td><td align="center" valign="middle" rowspan="1" colspan="1">93.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.965</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>b</italic></bold></td><td align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>a</italic></bold></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-TBGL IgG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5058</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">89.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.762</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold><italic>a</italic></bold></td></tr></tbody></table><table-wrap-foot><fn><p>A cutoff was calculated based on TB and HC data from the Youden index. The discriminatory power of each test was evaluated by the area under curve (AUC) comparison. <italic><bold>a</bold></italic>, <bold><italic>b</italic></bold>, a significant difference between the AUCs of the indicated tests; <bold><italic>a</italic></bold>, <italic>p</italic> &#x0003c; 0.05, <bold><italic>b</italic></bold>, <italic>p</italic> &#x0003c; 0.001.</p></fn></table-wrap-foot></table-wrap><table-wrap id="ijms-18-00019-t005" position="float"><object-id pub-id-type="pii">ijms-18-00019-t005_Table 5</object-id><label>Table 5</label><caption><p>Comparison of laboratory findings between TB patients with and without cavity lung formation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Normal Value (Range)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cavity (&#x02212;) (<italic>n</italic> = 24)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cavity (+) (<italic>n</italic> = 12)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hemoglobin (g/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">14&#x02013;18</td><td align="center" valign="middle" rowspan="1" colspan="1">13.8 (8.9&#x02013;17.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.4 (9.9&#x02013;14.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0454</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hematocrit (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">40&#x02013;48</td><td align="center" valign="middle" rowspan="1" colspan="1">42 (25.5&#x02013;51.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">37.5 (28.4&#x02013;41.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0208</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Monocyte (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">4&#x02013;7</td><td align="center" valign="middle" rowspan="1" colspan="1">6.2 (3.4&#x02013;10)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.3 (4.9&#x02013;10.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0054</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CRP (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">0&#x02013;0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">3.27 (0.04&#x02013;21.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.67 (0.08&#x02013;17.97)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0478</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IP-10 (pg/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">132.2&#x02013;472.8</td><td align="center" valign="middle" rowspan="1" colspan="1">751.5 (219.3&#x02013;2735)</td><td align="center" valign="middle" rowspan="1" colspan="1">1570 (369.7&#x02013;3051)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0408</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Anti-TBGL IgG (U/mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;2</td><td align="center" valign="middle" rowspan="1" colspan="1">13.3 (0.1&#x02013;62.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.11 (0&#x02013;72.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0123</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CXR Score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.46 (82.4&#x02013;100)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">131.84 (104.34&#x02013;140)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0001</td></tr></tbody></table></table-wrap><table-wrap id="ijms-18-00019-t006" position="float"><object-id pub-id-type="pii">ijms-18-00019-t006_Table 6</object-id><label>Table 6</label><caption><p>CXR score and biomarkers in TB patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Parameter</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">CXR Scorer (<italic>p</italic>)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">CXR Scorer (<italic>p</italic>)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cavity (+)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cavity (&#x02212;)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Monocytes (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.502 (0.003)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">OPN</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">sCD44</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IP-10</td><td align="center" valign="middle" rowspan="1" colspan="1">0.452 (0.027)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gal-9</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">IL-12p70</td><td align="center" valign="middle" rowspan="1" colspan="1">0.517 (0.01)</td><td align="center" valign="middle" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" rowspan="1" colspan="1">0.574 (0.032)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ESAT-6 SFC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ns</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.6185 (0.0425)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ns</td></tr></tbody></table><table-wrap-foot><fn><p>Ns: no significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="ijms-18-00019-t007" position="float"><object-id pub-id-type="pii">ijms-18-00019-t007_Table 7</object-id><label>Table 7</label><caption><p>Laboratory and biomarker values in patients infected by Beijing or non-Beijing strains of <italic>Mycobacterium tuberculosis</italic> (MTB).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HC</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Beijing Type (<italic>n</italic> = 20)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Non-Beijing Type (<italic>n</italic> = 16)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Laboratory findings</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;RBC (10<sup>6</sup>/&#x003bc;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">na.</td><td align="center" valign="middle" rowspan="1" colspan="1">4.28 (2.72&#x02013;5.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.64 (3.86&#x02013;5.57)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0465</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;Total protein (g/dL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">na.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.05 (5.41&#x02013;8.03)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.69 (6.54&#x02013;8.14)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0323</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biomarker (pg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;G-CSF</td><td align="center" valign="middle" rowspan="1" colspan="1">48.48 (12.19&#x02013;90.49)</td><td align="center" valign="middle" rowspan="1" colspan="1">56.94 (21.69&#x02013;106.36)</td><td align="center" valign="middle" rowspan="1" colspan="1">38.12 (14.06&#x02013;73.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0388</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;GM-CSF</td><td align="center" valign="middle" rowspan="1" colspan="1">4.24 (0.44&#x02013;18.98)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.29 (0.83&#x02013;48.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.84 (0.44&#x02013;14.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0300</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;IFN&#x003b1;</td><td align="center" valign="middle" rowspan="1" colspan="1">11.07 (0&#x02013;56.49)</td><td align="center" valign="middle" rowspan="1" colspan="1">32.87 (1.67&#x02013;60.81) <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">7.53 (0&#x02013;40.97)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0034</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;IFN&#x003b3;</td><td align="center" valign="middle" rowspan="1" colspan="1">4.46 (0.42&#x02013;19.38)</td><td align="center" valign="middle" rowspan="1" colspan="1">16.02 (3.09&#x02013;41) <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4.71 (2.12&#x02013;17.84)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0141</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;IL-12p70</td><td align="center" valign="middle" rowspan="1" colspan="1">2.74 (1.35&#x02013;15.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.22 (1.85&#x02013;29.77)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.62 (0.03&#x02013;7.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;IL-1RA</td><td align="center" valign="middle" rowspan="1" colspan="1">17.79 (0&#x02013;81.26)</td><td align="center" valign="middle" rowspan="1" colspan="1">51.96 (8.56&#x02013;217.37) <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">14.02 (0&#x02013;78.44)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0095</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;IP-10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">235.78 (132.2&#x02013;472.75)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">877.12 (219.29&#x02013;2814.69) <sup>a</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">864.57 (369.67&#x02013;3051.48) <sup>b</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cavity <italic>n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (40)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (25)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CXR score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102.23 (82.4&#x02013;140)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109.74 (82.77&#x02013;140)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;0.05</td></tr></tbody></table><table-wrap-foot><fn><p>Differences among the groups in terms of laboratory biomarkers were analyzed by the <italic>Kruskal-Wallis</italic> test; <italic>p</italic> &#x0003c; 0.05 indicates a significant difference between Beijing and non-Beijing MTB groups; <sup>a</sup> indicates a significant difference between groups Beijing MTB and HC, <italic>p</italic> &#x0003c; 0.05; <sup>b</sup> indicates a significant difference between groups non-Beijing MTB and HC; <italic>p</italic> &#x0003c; 0.05. na., no applicable.</p></fn></table-wrap-foot></table-wrap></floats-group></article>